<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1-3.dtd?>
<?SourceDTD.Version 1.3?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id>
    <journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id>
    <journal-id journal-id-type="publisher-id">ijms</journal-id>
    <journal-title-group>
      <journal-title>International Journal of Molecular Sciences</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1422-0067</issn>
    <publisher>
      <publisher-name>MDPI</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9916039</article-id>
    <article-id pub-id-type="doi">10.3390/ijms24031891</article-id>
    <article-id pub-id-type="publisher-id">ijms-24-01891</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>MiRNA Differences Related to Treatment-Resistant Schizophrenia</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8110-3567</contrib-id>
        <name>
          <surname>Pérez-Rodríguez</surname>
          <given-names>Daniel</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
        <xref rid="af1-ijms-24-01891" ref-type="aff">1</xref>
        <xref rid="af2-ijms-24-01891" ref-type="aff">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Penedo</surname>
          <given-names>Maria Aránzazu</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="af2-ijms-24-01891" ref-type="aff">2</xref>
        <xref rid="af3-ijms-24-01891" ref-type="aff">3</xref>
        <xref rid="fn1-ijms-24-01891" ref-type="author-notes">†</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Rivera-Baltanás</surname>
          <given-names>Tania</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="af2-ijms-24-01891" ref-type="aff">2</xref>
        <xref rid="fn1-ijms-24-01891" ref-type="author-notes">†</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Peña-Centeno</surname>
          <given-names>Tonatiuh</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="af4-ijms-24-01891" ref-type="aff">4</xref>
        <xref rid="fn1-ijms-24-01891" ref-type="author-notes">†</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Burkhardt</surname>
          <given-names>Susanne</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="af4-ijms-24-01891" ref-type="aff">4</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8546-1161</contrib-id>
        <name>
          <surname>Fischer</surname>
          <given-names>Andre</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="af4-ijms-24-01891" ref-type="aff">4</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8170-0724</contrib-id>
        <name>
          <surname>Prieto-González</surname>
          <given-names>José M.</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="af1-ijms-24-01891" ref-type="aff">1</xref>
        <xref rid="af5-ijms-24-01891" ref-type="aff">5</xref>
        <xref rid="af6-ijms-24-01891" ref-type="aff">6</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Olivares</surname>
          <given-names>José Manuel</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="af2-ijms-24-01891" ref-type="aff">2</xref>
        <xref rid="af7-ijms-24-01891" ref-type="aff">7</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6476-7206</contrib-id>
        <name>
          <surname>López-Fernández</surname>
          <given-names>Hugo</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
        <xref rid="af8-ijms-24-01891" ref-type="aff">8</xref>
        <xref rid="af9-ijms-24-01891" ref-type="aff">9</xref>
        <xref rid="c1-ijms-24-01891" ref-type="corresp">*</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9899-9569</contrib-id>
        <name>
          <surname>Agís-Balboa</surname>
          <given-names>Roberto Carlos</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
        <xref rid="af1-ijms-24-01891" ref-type="aff">1</xref>
        <xref rid="af2-ijms-24-01891" ref-type="aff">2</xref>
        <xref rid="af5-ijms-24-01891" ref-type="aff">5</xref>
        <xref rid="af6-ijms-24-01891" ref-type="aff">6</xref>
        <xref rid="c1-ijms-24-01891" ref-type="corresp">*</xref>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Kaphzan</surname>
          <given-names>Hanoch</given-names>
        </name>
        <role>Academic Editor</role>
      </contrib>
      <contrib contrib-type="editor">
        <name>
          <surname>Knafo</surname>
          <given-names>Shira</given-names>
        </name>
        <role>Academic Editor</role>
      </contrib>
    </contrib-group>
    <aff id="af1-ijms-24-01891"><label>1</label>NeuroEpigenetics Lab, Instituto de Investigación Sanitaria de Santiago (IDIS), Complejo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain</aff>
    <aff id="af2-ijms-24-01891"><label>2</label>Translational Neuroscience Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Área Sanitaria de Vigo-Hospital Álvaro Cunqueiro, SERGAS-UVIGO, CIBERSAM-ISCIII, 36213 Vigo, Spain</aff>
    <aff id="af3-ijms-24-01891"><label>3</label>Grupo de Neurofarmacología de Las Adicciones y Los Trastornos Degenerativos (NEUROFAN), Universidad CEU San Pablo, 28925 Madrid, Spain</aff>
    <aff id="af4-ijms-24-01891"><label>4</label>Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases, 37075 Göttingen, Germany</aff>
    <aff id="af5-ijms-24-01891"><label>5</label>Servicio de Neurología, Hospital Clínico Universitario de Santiago, 15706 Santiago de Compostela, Spain</aff>
    <aff id="af6-ijms-24-01891"><label>6</label>Grupo Trastornos del Movimiento, Instituto de Investigación Sanitaria de Santiago (IDIS), Complejo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain</aff>
    <aff id="af7-ijms-24-01891"><label>7</label>Department of Psychiatry, Área Sanitaria de Vigo, 36312 Vigo, Spain</aff>
    <aff id="af8-ijms-24-01891"><label>8</label>SING Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, 36213 Vigo, Spain</aff>
    <aff id="af9-ijms-24-01891"><label>9</label>CINBIO, Department of Computer Science, ESEI-Escuela Superior de Ingeniería Informática, Universidade de Vigo, 32004 Ourense, Spain</aff>
    <author-notes>
      <corresp id="c1-ijms-24-01891"><label>*</label>Correspondence: <email>hlfernandez@uvigo.es</email> (H.L.-F.); <email>roberto.carlos.agis.balboa@sergas.es</email> (R.C.A.-B.)</corresp>
      <fn id="fn1-ijms-24-01891">
        <label>†</label>
        <p>These authors contributed equally to this work.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="epub">
      <day>18</day>
      <month>1</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="collection">
      <month>2</month>
      <year>2023</year>
    </pub-date>
    <volume>24</volume>
    <issue>3</issue>
    <elocation-id>1891</elocation-id>
    <history>
      <date date-type="received">
        <day>24</day>
        <month>11</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd">
        <day>09</day>
        <month>1</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>12</day>
        <month>1</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2023 by the authors.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <p>Schizophrenia (SZ) is a serious mental disorder that is typically treated with antipsychotic medication. Treatment-resistant schizophrenia (TRS) is the condition where symptoms remain after pharmacological intervention, resulting in long-lasting functional and social impairments. As the identification and treatment of a TRS patient requires previous failed treatments, early mechanisms of detection are needed in order to quicken the access to effective therapy, as well as improve treatment adherence. In this study, we aim to find a microRNA (miRNA) signature for TRS, as well as to shed some light on the molecular pathways potentially involved in this severe condition. To do this, we compared the blood miRNAs of schizophrenia patients that respond to medication and TRS patients, thus obtaining a 16-miRNA TRS profile. Then, we assessed the ability of this signature to separate responders and TRS patients using hierarchical clustering, observing that most of them are grouped correctly (~70% accuracy). We also conducted a network, pathway analysis, and bibliography search to spot molecular pathways potentially altered in TRS. We found that the response to stress seems to be a key factor in TRS and that proteins p53, SIRT1, MDM2, and TRIM28 could be the potential mediators of such responses. Finally, we suggest a molecular pathway potentially regulated by the miRNAs of the TRS profile.</p>
    </abstract>
    <kwd-group>
      <kwd>treatment resistant schizophrenia</kwd>
      <kwd>microRNA</kwd>
      <kwd>biomarkers</kwd>
      <kwd>p53</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>Instituto de Salud Carlos III</funding-source>
        <award-id>PI18/01311</award-id>
      </award-group>
      <award-group>
        <funding-source>European Regional Development Fund</funding-source>
        <award-id>PI18/01311</award-id>
      </award-group>
      <award-group>
        <funding-source>Xunta de Galicia</funding-source>
      </award-group>
      <award-group>
        <funding-source>Conselleria de Cultura, Educación e Universidade</funding-source>
        <award-id>ED431C 2022/03-GRC</award-id>
      </award-group>
      <funding-statement>This research was funded by Instituto de Salud Carlos III (ISCIII) through the project PI18/01311 (co-funded by European Regional Development Fund (FEDER), “A way to make Europe”, UE) to R.C. Agís-Balboa. D. Pérez-Rodríguez is supported by an “Investigo Program” predoctoral contract from Xunta de Galicia. This work was also partially supported by the Conselleria de Cultura, Educación e Universidade (Xunta de Galicia), under the scope of the strategic funding ED431C 2022/03-GRC Competitive Reference Group and by Ministerio de Universidades (Gobierno de España) through a “María Zambrano” contract (Hugo López-Fernández).</funding-statement>
    </funding-group>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="sec1-ijms-24-01891">
    <title>1. Introduction</title>
    <p>Schizophrenia (SZ) is a heterogeneous psychiatric disorder that affects around 1% of the world’s population [<xref rid="B1-ijms-24-01891" ref-type="bibr">1</xref>], and it is characterised by chronic psychotic symptoms and psychosocial impairment. Since the development of chlorpromazine in the 1950s, treatment for SZ is based on antipsychotic medications; however, about 20 to 50 percent of patients do not experience an improvement in their symptoms [<xref rid="B2-ijms-24-01891" ref-type="bibr">2</xref>,<xref rid="B3-ijms-24-01891" ref-type="bibr">3</xref>,<xref rid="B4-ijms-24-01891" ref-type="bibr">4</xref>,<xref rid="B5-ijms-24-01891" ref-type="bibr">5</xref>], which is known as treatment-resistant schizophrenia (TRS). The clinical definition of TRS is based on the failure of response to at least two sequential non-clozapine antipsychotic trials of sufficient dose, duration, and adherence [<xref rid="B6-ijms-24-01891" ref-type="bibr">6</xref>]. Patients with TRS have higher rates of substance abuse, early cognitive decline, and higher rates of suicide ideation [<xref rid="B7-ijms-24-01891" ref-type="bibr">7</xref>,<xref rid="B8-ijms-24-01891" ref-type="bibr">8</xref>,<xref rid="B9-ijms-24-01891" ref-type="bibr">9</xref>,<xref rid="B10-ijms-24-01891" ref-type="bibr">10</xref>]. As pharmacological and therapeutic approaches differ between SZ and TRS [<xref rid="B11-ijms-24-01891" ref-type="bibr">11</xref>,<xref rid="B12-ijms-24-01891" ref-type="bibr">12</xref>,<xref rid="B13-ijms-24-01891" ref-type="bibr">13</xref>,<xref rid="B14-ijms-24-01891" ref-type="bibr">14</xref>], early identification of the resistance condition is essential for a rapid and effective pharmacological intervention, limiting damage to the patient and their environment and improving the adherence to treatment [<xref rid="B15-ijms-24-01891" ref-type="bibr">15</xref>]. As a consequence, in the last two decades, an increasing number of studies have made great efforts to find molecular mechanisms behind TRS and spot biomarkers for clinical use. However, the difficult access to neural tissues, the subtle definition of TRS, and the lack of standardization in the bioinformatic methodologies hindered such endeavors [<xref rid="B15-ijms-24-01891" ref-type="bibr">15</xref>,<xref rid="B16-ijms-24-01891" ref-type="bibr">16</xref>,<xref rid="B17-ijms-24-01891" ref-type="bibr">17</xref>,<xref rid="B18-ijms-24-01891" ref-type="bibr">18</xref>,<xref rid="B19-ijms-24-01891" ref-type="bibr">19</xref>].</p>
    <p>In the last decade, micro-RNAs (miRNAs) emerged as promising biomarkers for mental conditions [<xref rid="B16-ijms-24-01891" ref-type="bibr">16</xref>,<xref rid="B20-ijms-24-01891" ref-type="bibr">20</xref>]. These molecules are small non-coding RNAs involved in the post-transcriptional regulation of gene expression. Their presence in almost all biological processes makes them easy to sample, whereas their susceptibility to everyday events, such as sleep, stress, or medications, gives them potential as biomarkers [<xref rid="B21-ijms-24-01891" ref-type="bibr">21</xref>]. In this study, we employed NGS sequencing to characterise the complete blood miRNAome of schizophrenia patients differing in their response to antipsychotic treatment. To carry out the bioinformatics analyses, first we employed the highly replicable pipeline “myBrain-Seq v0.1.0” [<xref rid="B22-ijms-24-01891" ref-type="bibr">22</xref>,<xref rid="B23-ijms-24-01891" ref-type="bibr">23</xref>] for raw data preprocessing and differential expression analysis for defining a miRNA profile associated with the TRS condition (TRS profile). Then, we performed a hierarchical clustering analysis for exploring the sample grouping based on the TRS profile, using the R package hclust [<xref rid="B24-ijms-24-01891" ref-type="bibr">24</xref>], and a functional analysis to explore some potential biological implications, using Cytoscape v3.9.1 [<xref rid="B25-ijms-24-01891" ref-type="bibr">25</xref>] and StringApp v2.0.0 [<xref rid="B26-ijms-24-01891" ref-type="bibr">26</xref>] tools. Our aim is twofold: first, to find a miRNA signature involved in TRS and second, to suggest its molecular roles and biological context. As a result, we found 16 miRNAs potentially involved in poor response to antipsychotic medication. Using this 16-miRNA signature, we were able to accurately classify more than two-thirds of our SZ and TRS samples and propose a molecular pathway in which these miRNAs could be involved, thus offering an interesting direction in which future research on TRS could be oriented.</p>
  </sec>
  <sec sec-type="results" id="sec2-ijms-24-01891">
    <title>2. Results</title>
    <sec id="sec2dot1-ijms-24-01891">
      <title>2.1. Profile of 16 miRNAs for Antipsychotic Resistance</title>
      <p>The quality of the samples, the sequencing depth, and the proportion of assigned and mapped sequences can be consulted in <xref rid="app1-ijms-24-01891" ref-type="app">Supplementary Table S1</xref>. Differential expression analysis of the miRNAome of schizophrenia patients with a normal antipsychotic response (MR) vs. schizophrenia patients with antipsychotic resistance (MNR) shows a total of 16 differentially expressed miRNAs potentially related to antipsychotic resistance (TRS profile), including 6 miRNAs whose expression was upregulated and 10 miRNAs that were downregulated. As shown in <xref rid="ijms-24-01891-f001" ref-type="fig">Figure 1</xref>A, the miRNAs differentially expressed in the resistant schizophrenia, compared to non-resistance schizophrenia, are miR-3127-3p (↑), miR-504-5p (↑), miR-3605-3p (↑), miR-6747-3p (↑), miR-3615 (↑), miR-1343-3p (↑), miR-145-5p (↓), miR-500a-3p (↓), miR-210-3p (↓), miR-199a-5p (↓), miR-548ay-3p (↓), miR-548ac (↓), miR-296-5p (↓), miR-660-5p (↓), miR-30b-5p (↓), and miR-223-3p (↓).</p>
    </sec>
    <sec id="sec2dot2-ijms-24-01891">
      <title>2.2. Hierarchical Clustering Analysis Using the TRS Profile</title>
      <p>As we described in materials and methods, hierarchical clustering was performed twice: using samples in both MR and MNR groups and using samples in the MR, MNR, and first psychotic episode at hospital arrival (PA) groups. We assessed the Positive and Negative Syndrome Scale (PANSS) and the Self-assessment Anhedonia Scale (SAAS) scores as a way to improve the discriminative power of the TRS profile (<xref rid="ijms-24-01891-f001" ref-type="fig">Figure 1</xref>B); however, they show a high overlap between groups and, therefore, were discarded.</p>
      <p>In the first dendrogram of MR and MNR samples (<xref rid="ijms-24-01891-f001" ref-type="fig">Figure 1</xref>C), two groups were differentiated. Cluster 1 had 73.2% of the MR samples, and cluster 2 had 72.4% of the MNR samples.</p>
      <p>In the second dendrogram of the MR, MNR, and PA samples (<xref rid="ijms-24-01891-f001" ref-type="fig">Figure 1</xref>D), 3 groups were differentiated: in cluster 1, 73.81% of samples were MR; in cluster 2, 59.38% of samples were MNR; and in cluster 3, 55.6% were MNR samples. Regarding the PA samples, four of them fell in cluster 1, nine in cluster 2, and none of them fell in cluster 3. Cluster 2 had 7 of the 9 PA<sub>R</sub> samples (77.78%) and 1 PA<sub>NR</sub> (22.22%). Cluster 1 had the remaining 2 PA<sub>R</sub> and PA<sub>NR</sub> samples (50% each). If we remove PA samples, cluster 1 has 78.9% of the MR samples, and cluster 2 has 73.9% of the MNR samples. From now on, we will refer to cluster 1 as “MR cluster” and to cluster 2 as “MNR cluster”.</p>
    </sec>
    <sec id="sec2dot3-ijms-24-01891">
      <title>2.3. Functional Analysis</title>
      <p>The first step of the functional analysis was the target prediction. Tarbase v8 [<xref rid="B27-ijms-24-01891" ref-type="bibr">27</xref>] predicted 13,267 targets for the 16 miRNAs of the miRNA signature. Four miRNAs, namely, hsa-miR-548ac, hsa-miR-548ay-3p, hsa-miR-660-5p, and hsa-miR-6747-3p, did not have any predicted target. Three miRNAs had overrepresented annotations, encompassing almost 75% of the total of predictions; these miRNAs were hsa-miR-210-3p, hsa-miR-1343-3p, and hsa-miR-30b-5p. Conversely, two of them had very few annotations, representing 0.86% (hsa-miR-223-3p) and 0.76% (hsa-miR-3605-3p) of the total number of annotations. More details of the results can be seen in <xref rid="ijms-24-01891-t001" ref-type="table">Table 1</xref>. The ten most common targets were: ANKRD52 (shared by eight miRNAs), SPEN (seven), MIDN (seven), SRRM2 (six), SON (six), MDM2 (six), LONRF2 (six), LARP1 (six), FBXL19 (six), and DDX3X (six). More details of the results of the target prediction can be seen in <xref rid="app1-ijms-24-01891" ref-type="app">Supplementary Table S2</xref>.</p>
      <p>The second step of the functional analysis was a bibliographic search of relevant miRNA targets of the miRNA signature. We found 10 genes (<xref rid="ijms-24-01891-t001" ref-type="table">Table 1</xref>) directly or indirectly regulated by any of the 16 miRNAs. The main functions implicated were related to the signal transducer and activator of transcription 3 (STAT3) and with several of its repressors (SOCS2, SOCS4, PTPN11). We also found some targets related to the multidrug resistance-associated proteins (ABCC1, ABCB1) and drug metabolism (CYP2C19).</p>
      <p>The last step was the network analysis and the functional enrichment of Pathways and GO terms. The most connected sub-network seems to be related to the AP-1 Transcription Factor Subunits (<xref rid="ijms-24-01891-f002" ref-type="fig">Figure 2</xref>). We found an interesting implication of hsa-miR-504-5p, hsa-miR-199a-5p, and hsa-miR-3615 in the regulation of transcription factors recognizing the cAMP response elements (CRE) sequence 5′-TGACGTCA-3′. Hsa-miR-504–5p seems to represses the transcription of “MAF BZIP Transcription Factor G” (MAFG), which directly interacts with the “Basic Leucine Zipper ATF-Like Transcription Factor 3” (BATF3) [<xref rid="B35-ijms-24-01891" ref-type="bibr">35</xref>]. BATF3 is known to dimerize with the “Transcription Factor AP-1 Subunit Jun” (JUN) acting as transcriptional repressor of CRE elements [<xref rid="B36-ijms-24-01891" ref-type="bibr">36</xref>,<xref rid="B37-ijms-24-01891" ref-type="bibr">37</xref>]. On the contrary, hsa-miR-199a-5p has been proved to target JUN and JUNB transcripts, both of which dimerize with BATF3 and “Activating Transcription Factor 4” (ATF4) [<xref rid="B38-ijms-24-01891" ref-type="bibr">38</xref>]. Moreover, hsa-miR-3615 directly represses “CREB/ATF BZIP Transcription Factor” (CREBZF) transcript, which is a known repressor of the “CAMP Responsive Element Binding Protein 3” (CREB-3), a transcription factor that binds to the CRE pattern [<xref rid="B39-ijms-24-01891" ref-type="bibr">39</xref>]. Finally, the DNA Methyltransferase 1 (DNMT1) and the Sirtuin 1 (SIRT1) are also implied in this subnetwork. SIRT1 deacetylates DNMT1, which is a target of hsa-miR-504-5p [<xref rid="B40-ijms-24-01891" ref-type="bibr">40</xref>]. It is worth noting the presence of more miRNA–targets interactions in this subnetwork. These interactions are hidden due to the degree filter applied to declutter the network in order to spot the most connected (and therefore, potentially relevant) nodes.</p>
      <p>The top 5 pathways enriched in the Reactome database were, in order of presence in our network: 17.75% of the genes related with the metabolism of proteins (q-value = 5.03<sup>−52</sup>), 14.42% related with the transcription of genes (q-value = 1.6<sup>−51</sup>), 14.12% related to diseases (q-value = 3.89<sup>−42</sup>), 8.04% associated with RNA metabolism (q-value = 1.99<sup>−40</sup>), and 7.48% with a cellular response to stress (q-value = 1.73<sup>−44</sup>). Regarding the WikiPathway database, the top 5 enriched pathways were: 5.51% of genes related to VEGFA-VEGFR2 signaling (q-value = 4.44<sup>−29</sup>), 3.47% related to miRNA effects in Alzheimer’s disease (q-value = 3.6<sup>−19</sup>), 2.39% related to breast cancer (q-value = 1.39<sup>−16</sup>), 1.75% related to the androgen receptor signalling pathway (q-value = 1.94<sup>−15</sup>), and 1.72% related to ionising radiation damage to DNA and the subsequent cellular response via the ATR Serine/Threonine Kinase (q-value = 8.38<sup>−17</sup>). Finally, in the KEGG database, the top 5 enriched pathways were: 3.98% of genes related to amyotrophic lateral sclerosis neurodegenerative disorder (q-value = 4.07<sup>−17</sup>), 3.36% related to Huntington neurodegenerative disease (q-value = 1.41<sup>−14</sup>), 3.28% of the genes related to intestinal infection caused by Shigella (q-value = 3.57<sup>−21</sup>), 2.96% related to Parkinson neurodegenerative disorder (q-value 9.04<sup>−15</sup>), and 2.66% related to viral infection and human carcinogenesis (q-value = 6.45<sup>−17</sup>).</p>
      <p>If we look at the genes in these pathways, we can notice that 10 of the 15 enriched pathways have TP53, PSMD4, PSMC1, and MDM2 proteins in common, and 9 pathways also have in common several 26S proteasome non-ATPase regulatory subunits, along with MTOR, EP300, CYCS, and CREBBP.</p>
    </sec>
  </sec>
  <sec sec-type="discussion" id="sec3-ijms-24-01891">
    <title>3. Discussion</title>
    <p>Schizophrenia is a severe mental disorder that affects around 1% of the world’s population [<xref rid="B1-ijms-24-01891" ref-type="bibr">1</xref>]. The current approach for its treatment is antipsychotic medication, but about one-fifth to one-half of patients do not respond to this pharmacological therapy [<xref rid="B15-ijms-24-01891" ref-type="bibr">15</xref>]. Patients with resistant schizophrenia have poorer outcomes than patients with other severe mental illnesses, experiencing higher degrees of inadaptation to daily demands [<xref rid="B41-ijms-24-01891" ref-type="bibr">41</xref>], which is an indication of a bad prognosis. Here, we present 16 miRNAs that are potentially related to treatment-resistant schizophrenia, and that will be a good starting point to biologically understand this condition and develop biological biomarkers.</p>
    <sec id="sec3dot1-ijms-24-01891">
      <title>3.1. miRNAs Previously Associated with Psychiatric Conditions</title>
      <p>Seven of these 16 miRNAs have been previously related to neuropsychiatric conditions: <bold>miR-199a-5p</bold> (downregulated in MNR) has been found to target the IFNAR1 gene in a Dual-Luciferase Reporter Assay in a cell-based Parkinson’s disease model [<xref rid="B42-ijms-24-01891" ref-type="bibr">42</xref>]. This gene encodes for type I Interferon Receptor 1, whose depletion in the organism seems to be protective against cognitive decline in mouse models of Alzheimer’s disease [<xref rid="B43-ijms-24-01891" ref-type="bibr">43</xref>], and its presence in the human entorhinal cortex is proposed as a potential indicator of this condition [<xref rid="B44-ijms-24-01891" ref-type="bibr">44</xref>]. Downregulation of this miRNA was also observed in dopaminergic neurons of Parkinson patients [<xref rid="B45-ijms-24-01891" ref-type="bibr">45</xref>]. <bold>MiR-296-5p</bold> (downregulated in MNR) was found to be upregulated in schizophrenia patients compared to healthy controls [<xref rid="B46-ijms-24-01891" ref-type="bibr">46</xref>]. <bold>MiR-504</bold> (upregulated in MNR) has been found to target the SHANK3 gene in a luciferase assay in cultured mouse hippocampal neurons [<xref rid="B47-ijms-24-01891" ref-type="bibr">47</xref>]. This gene encodes for scaffold proteins of the postsynaptic density, and it is also related to synapse formation and dendritic spine maturation; alterations in this gene are related to autism spectrum disorder and schizophrenia type 15 [<xref rid="B48-ijms-24-01891" ref-type="bibr">48</xref>]. Moreover, this miRNA was found to be overexpressed in post-mortem brain tissue of patients with bipolar disorder, but not in schizophrenia patients, when compared to healthy controls [<xref rid="B49-ijms-24-01891" ref-type="bibr">49</xref>]. <bold>MiR-660-5p</bold> (downregulated in MNR) was upregulated in the serum of patients with Alzheimer disease compared to healthy controls [<xref rid="B50-ijms-24-01891" ref-type="bibr">50</xref>], but was found to be underexpressed in Long-Evans rats exposed to ethanol intake when compared to healthy control rats [<xref rid="B51-ijms-24-01891" ref-type="bibr">51</xref>]. <bold>MiR-3615</bold> (upregulated in MNR) was included in a 2020 study as one of a seven-miRNA profile for the discrimination of schizophrenia from controls [<xref rid="B52-ijms-24-01891" ref-type="bibr">52</xref>]. A downregulation in <bold>miR-30b-5p</bold> levels (downregulated in MNR) was observed in patients with BD in comparison to healthy controls [<xref rid="B53-ijms-24-01891" ref-type="bibr">53</xref>]. Finally, <bold>miR-6747-3p</bold> (upregulated in MNR) was found to be upregulated in the serum of Alzheimer’s disease patients compared to healthy controls [<xref rid="B54-ijms-24-01891" ref-type="bibr">54</xref>].</p>
    </sec>
    <sec id="sec3dot2-ijms-24-01891">
      <title>3.2. miRNAs Potentially Related to Drug Resistance</title>
      <p>A total of 3 of these 16 miRNAs have been previously related to the resistance to other medications. <bold>miR-145-5p</bold> (downregulated in MNR) has been linked to the acquired resistance to cisplatin and fluorouracil combination-based chemotherapy in gastric cancer patients [<xref rid="B55-ijms-24-01891" ref-type="bibr">55</xref>] and also found to be underexpressed in patients with bipolar disorder type I when compared to healthy controls [<xref rid="B56-ijms-24-01891" ref-type="bibr">56</xref>].</p>
      <p>Downregulation of <bold>miR-210-3p</bold> (downregulated in MNR) has been related to an increase in ABCC1 expression in renal carcinoma and a subsequent reduction in chemotherapy drug sensitivity. The ABCC1 gene encodes for the multidrug resistance-associated protein 1; a member of the superfamily of ATP-binding cassette (ABC) transporters, it is related to multidrug resistance. Single nucleotide polymorphisms in this gene were associated with alterations in clozapine and norclozapine serum levels [<xref rid="B57-ijms-24-01891" ref-type="bibr">57</xref>].</p>
      <p>Finally, a 2020 study [<xref rid="B29-ijms-24-01891" ref-type="bibr">29</xref>] found an upregulation of <bold>miR-1343-3p</bold> (upregulated in MNR) in the presence of the mutant allele rs4244285 of the CYP2C19 gene, which encodes a member of the cytochrome P450 enzyme superfamily. This rs4244285 allele encodes the CYP2C19*2 variant, which is known to be related to poor metabolism of compounds, such as some antidepressants, including fluvoxamine or sertraline hydrochloride [<xref rid="B58-ijms-24-01891" ref-type="bibr">58</xref>,<xref rid="B59-ijms-24-01891" ref-type="bibr">59</xref>]; anticonvulsants, such as valproic acid [<xref rid="B60-ijms-24-01891" ref-type="bibr">60</xref>]; and benzodiazepines, such as phenazepam [<xref rid="B61-ijms-24-01891" ref-type="bibr">61</xref>], among others. Moreover, CYP2C19 product is an enzyme responsible for the metabolization of clozapine [<xref rid="B62-ijms-24-01891" ref-type="bibr">62</xref>,<xref rid="B63-ijms-24-01891" ref-type="bibr">63</xref>].</p>
    </sec>
    <sec id="sec3dot3-ijms-24-01891">
      <title>3.3. Interpretation of the Hierarchical Clustering</title>
      <p>In the dendrogram of MR and MNR samples (<xref rid="ijms-24-01891-f001" ref-type="fig">Figure 1</xref>C), a clear separation between the MR and MNR samples can be seen. Some pairs of samples (arrival and departure) are together in the MNR cluster (MR010A/D, MR011A/D, and MR012A/D) and in the MR cluster (MNR018A/D, MNR001A/D, and MNR019A/D). This probably means that the hospital environment did not significantly change their miRNA expression before and after hospitalisation, either due to similar environment variables (e.g., same hours of sleep, meals, light exposure, …) or pharmacological factors (e.g., the same medication is maintained). Interestingly, three pairs of samples (MR014A/D, MR018A/D, and MNR002A/D) change from the MNR cluster to the MR cluster after hospitalisation, whereas in two samples (MNR005A/D and MR017A/D), the opposite phenomena is observed. A change between the MNR cluster to the MR cluster could be the consequence of the hospital’s regular administration of the medication in an adequate dose, contrasting with a previous pharmacological deregularization [<xref rid="B64-ijms-24-01891" ref-type="bibr">64</xref>,<xref rid="B65-ijms-24-01891" ref-type="bibr">65</xref>]. This explanation is the most feasible, as two of these three samples were from patients treated with multiple antipsychotics, and the third one came from a MR patient treated with clozapine.</p>
      <p>On the contrary, a change between the MR cluster to the MNR cluster is more difficult to explain. This implies either a MNR or MR patient was more similar to a MR patient initially, and after hospitalisation, became more similar to an MNR; in other words, a theoretical worsening of the treatment response after hospitalisation.</p>
      <p>In the dendrogram of MR, MNR, and PA samples (<xref rid="ijms-24-01891-f001" ref-type="fig">Figure 1</xref>D), it can be observed that the miRNA expression of the TRS profile is more similar between PA samples and MNR samples (7 of 9 PA samples clustered in the MNR cluster, made of 73.9% MNR samples). In other words, MNR samples (treated patients) are more similar to PA (untreated) than to MR (treated). Interestingly, 4 PA samples clustered in the MR cluster, made of 78.9% MR samples. If we look at the clinical records of these four patients, we can observe that P010A and P011A had pathologies unrelated to schizophrenia—the first one, dementia related to a brain tumour and the second one, active consumption of toxic substances and aggressiveness not attributed to a psychiatric pathology. On the contrary, P008A figures as a stable non-medicated patient since the last two years, and P007A had an important mental disability previous to the psychotic episode. All this suggests that the PA samples of the MR cluster probably have conditions not intrinsically related to schizophrenia.</p>
    </sec>
    <sec id="sec3dot4-ijms-24-01891">
      <title>3.4. Interpretation of the Functional Analysis</title>
      <p>Although at a first glance, the results of the pathway enrichment analysis could seem divergent, most of the pathways have something in common: they are related to the exposure and response of the organism to a stressor. The vulnerability–stress model has been proposed as a broad explanation for the schizophrenia aetiology since the 1980s [<xref rid="B66-ijms-24-01891" ref-type="bibr">66</xref>,<xref rid="B67-ijms-24-01891" ref-type="bibr">67</xref>], and it is currently used as an explanation of their aetiology and prodromes [<xref rid="B68-ijms-24-01891" ref-type="bibr">68</xref>,<xref rid="B69-ijms-24-01891" ref-type="bibr">69</xref>,<xref rid="B70-ijms-24-01891" ref-type="bibr">70</xref>]. Experimental evidence, such as the association between the level of activation of the inflammatory response and schizophrenia, seems to suggest a role for stress in this condition [<xref rid="B71-ijms-24-01891" ref-type="bibr">71</xref>,<xref rid="B72-ijms-24-01891" ref-type="bibr">72</xref>,<xref rid="B73-ijms-24-01891" ref-type="bibr">73</xref>,<xref rid="B74-ijms-24-01891" ref-type="bibr">74</xref>]. Moreover, differences in this inflammatory response have also been noticed between schizophrenia and treatment-resistant schizophrenia [<xref rid="B73-ijms-24-01891" ref-type="bibr">73</xref>,<xref rid="B75-ijms-24-01891" ref-type="bibr">75</xref>,<xref rid="B76-ijms-24-01891" ref-type="bibr">76</xref>,<xref rid="B77-ijms-24-01891" ref-type="bibr">77</xref>,<xref rid="B78-ijms-24-01891" ref-type="bibr">78</xref>].</p>
      <p>If we closely look at the enriched pathways in <xref rid="ijms-24-01891-t002" ref-type="table">Table 2</xref>, we can notice that most of them have Tumor Protein P53 (TP53) and its regulator MDM2 Proto-Oncogene (MDM2) in common, both heavily involved in the cellular stress response. MDM2 is a primary negative regulatory factor of p53 (the TP53 product) and contributes to its normal expression in the cell. This is achieved by the ubiquitination of p53 by MDM2, which leads to the p53 degradation [<xref rid="B79-ijms-24-01891" ref-type="bibr">79</xref>]. On the other side, the protein p53 is a tumour suppressor, which responds to diverse cellular stresses to regulate expression of its target genes; it is involved in the regulation of processes such as cell cycle arrest, apoptosis, senescence, DNA repair, and changes in metabolism. The MDM2/p53 pathway has been found to play an important role in drug resistance [<xref rid="B80-ijms-24-01891" ref-type="bibr">80</xref>,<xref rid="B81-ijms-24-01891" ref-type="bibr">81</xref>,<xref rid="B82-ijms-24-01891" ref-type="bibr">82</xref>,<xref rid="B83-ijms-24-01891" ref-type="bibr">83</xref>], and its regulatory expression was found to be altered during treatments with the antipsychotic fluspirilene [<xref rid="B84-ijms-24-01891" ref-type="bibr">84</xref>]. Interestingly, the association between the schizophrenia condition and the risk for cancer development has been debated for more than 100 years [<xref rid="B85-ijms-24-01891" ref-type="bibr">85</xref>,<xref rid="B86-ijms-24-01891" ref-type="bibr">86</xref>,<xref rid="B87-ijms-24-01891" ref-type="bibr">87</xref>,<xref rid="B88-ijms-24-01891" ref-type="bibr">88</xref>,<xref rid="B89-ijms-24-01891" ref-type="bibr">89</xref>,<xref rid="B90-ijms-24-01891" ref-type="bibr">90</xref>,<xref rid="B91-ijms-24-01891" ref-type="bibr">91</xref>]. The results indicate both a decrease and an increase in the risk of cancer, which varies according to the type of tumour studied and the schizophrenia cohort [<xref rid="B90-ijms-24-01891" ref-type="bibr">90</xref>]; still, the evidence shows that the mechanisms that regulate tumorigenesis seem to be closely related to this condition.</p>
    </sec>
    <sec id="sec3dot5-ijms-24-01891">
      <title>3.5. A Molecular Model for Treatment Resistant Schizophrenia</title>
      <p>In an effort to integrate the results of the DEA, the network and pathway analysis, the miRNA target prediction, and the bibliographic search, we propose in <xref rid="ijms-24-01891-f003" ref-type="fig">Figure 3</xref> a pathway in which the DE miRNAs could be potentially implied. Hopefully, it could bring a hint about the treatment-resistant schizophrenia aetiology.</p>
      <p>We found that p53/MDM2 interaction could possibly be the key to explain the observed differences in miRNA expression between the MR and MNR groups. First, both molecules were the most recurrent similarity in the top five enriched pathways in three different databases. Second, MDM2 and its regulators, MAGE Family Member C2 (MAGEC2) and (RING Finger Protein 96) TRIM28, were targeted by eight different miRNAs of the TRS profile. Third, SIRT1 and its deacetylation substrate, DNMT1, are both present in the most connected subnetwork and have a direct involvement in the regulation of p53 transcription. Finally, bibliographic evidence supports the proposed pathway in four aspects: (i) the implication of p53/MDM2 in the multidrug resistance process [<xref rid="B80-ijms-24-01891" ref-type="bibr">80</xref>,<xref rid="B81-ijms-24-01891" ref-type="bibr">81</xref>,<xref rid="B82-ijms-24-01891" ref-type="bibr">82</xref>,<xref rid="B83-ijms-24-01891" ref-type="bibr">83</xref>], (ii) the involvement of p53 in autophagy, a process known to be related to antipsychotic response [<xref rid="B92-ijms-24-01891" ref-type="bibr">92</xref>,<xref rid="B93-ijms-24-01891" ref-type="bibr">93</xref>,<xref rid="B94-ijms-24-01891" ref-type="bibr">94</xref>,<xref rid="B95-ijms-24-01891" ref-type="bibr">95</xref>]; (iii) the observed dysregulations of this pathway in schizophrenia patients [<xref rid="B96-ijms-24-01891" ref-type="bibr">96</xref>,<xref rid="B97-ijms-24-01891" ref-type="bibr">97</xref>,<xref rid="B98-ijms-24-01891" ref-type="bibr">98</xref>], and (iv) the relationship of this pathway to negative symptoms, such as memory, learning ability impairment [<xref rid="B99-ijms-24-01891" ref-type="bibr">99</xref>], and major depression [<xref rid="B100-ijms-24-01891" ref-type="bibr">100</xref>].</p>
      <p>In this pathway, SIRT1 deacetylates the methyltransferase DNMT1. This results in an activation or repression of its methyltransferase activity, which varies with the deacetylation position [<xref rid="B40-ijms-24-01891" ref-type="bibr">40</xref>]. For its part, increased levels of DNMT1 seem to enhance the methylation in the TP53 promoter, leading to the downregulation of p53 [<xref rid="B101-ijms-24-01891" ref-type="bibr">101</xref>,<xref rid="B102-ijms-24-01891" ref-type="bibr">102</xref>,<xref rid="B103-ijms-24-01891" ref-type="bibr">103</xref>]. Moreover, SIRT1 has also been found to directly deacetylate p53, repressing its transactivation [<xref rid="B104-ijms-24-01891" ref-type="bibr">104</xref>,<xref rid="B105-ijms-24-01891" ref-type="bibr">105</xref>,<xref rid="B106-ijms-24-01891" ref-type="bibr">106</xref>], and play a role in the modulation of the response to stress. Two recent examples of this are the observed increment in levels of p53 and decreased levels of SIRT1 in mice brain after long-term “ultraviolet A” eye radiation [<xref rid="B99-ijms-24-01891" ref-type="bibr">99</xref>], as well as the inverse phenomena after acute heat stress in bovine granulosa cells, where decreased levels of p53 and increased levels of SIRT1 were observed [<xref rid="B107-ijms-24-01891" ref-type="bibr">107</xref>]. In MNR, SIRT1 is potentially targeted by the underexpressed hsa-miR-30b-5p, whereas DNMT1 is by the overexpressed hsa-miR-504-5p (<xref rid="ijms-24-01891-f003" ref-type="fig">Figure 3</xref>).</p>
      <p>Other regulators of p53 are MDM2 and MAGEC2. The MDM2 transcript is heavily targeted by the miRNAs of our TRS profile, and its protein product is well-known for its role in p53 inactivation [<xref rid="B83-ijms-24-01891" ref-type="bibr">83</xref>,<xref rid="B108-ijms-24-01891" ref-type="bibr">108</xref>,<xref rid="B109-ijms-24-01891" ref-type="bibr">109</xref>]. Under nonstressed conditions, MDM2 regulates p53 expression through an autoregulatory feedback loop [<xref rid="B110-ijms-24-01891" ref-type="bibr">110</xref>,<xref rid="B111-ijms-24-01891" ref-type="bibr">111</xref>,<xref rid="B112-ijms-24-01891" ref-type="bibr">112</xref>]. This regulation can be made by the direct binding of MDM2 to p53 transactivation domain, by MDM2 involvement in the nuclear translocation of p53, or by promoting its degradation using its ubiquitin ligase activity [<xref rid="B108-ijms-24-01891" ref-type="bibr">108</xref>,<xref rid="B113-ijms-24-01891" ref-type="bibr">113</xref>]. MDM2/p53 regulation has been extensively linked to drug resistance [<xref rid="B80-ijms-24-01891" ref-type="bibr">80</xref>,<xref rid="B81-ijms-24-01891" ref-type="bibr">81</xref>,<xref rid="B114-ijms-24-01891" ref-type="bibr">114</xref>], and there is evidence of its regulatory interaction being disrupted by some antipsychotics, such as fluspirilene and pimozide, or mood stabilisers, such as lithium [<xref rid="B84-ijms-24-01891" ref-type="bibr">84</xref>,<xref rid="B115-ijms-24-01891" ref-type="bibr">115</xref>,<xref rid="B116-ijms-24-01891" ref-type="bibr">116</xref>]. In MNR, MDM2 is potentially targeted by seven miRNAs of the TRS profile (<xref rid="ijms-24-01891-f003" ref-type="fig">Figure 3</xref>), four downregulated (hsa-miR-3127-3p, hsa-miR-210-3p, hsa-miR-145-5p, and hsa-miR-30b-5p) and three overexpressed (hsa-miR-1343-3p, hsa-miR-3127-3p, and hsa-miR-504-5p).</p>
      <p>Regarding MDM2 regulators, an important modulator of MDM2 ubiquitin ligase activity is MAGEC2, which has recently been found to inhibit the ubiquitination of p53 by directly interacting with the MHD domain of MDM2 [<xref rid="B117-ijms-24-01891" ref-type="bibr">117</xref>]. At the same time, TRIM28 competes with MDM2 for MAGEC2 binding, thus acting as a promoter of MDM2 ubiquitin ligase activity and, consequently, triggering p53 degradation [<xref rid="B117-ijms-24-01891" ref-type="bibr">117</xref>,<xref rid="B118-ijms-24-01891" ref-type="bibr">118</xref>]. In MNR, TRIM28 is potentially targeted by four miRNAs of the TRS profile (<xref rid="ijms-24-01891-f003" ref-type="fig">Figure 3</xref>), two overexpressed (hsa-miR-3605-3p, hsa-miR-1343-3p) and two downregulated (hsa-miR-296-5p, hsa-miR-145-5p).</p>
      <p>Finally, the acetylation of p53 is enhanced as a stress response, which results in its transcriptional activation [<xref rid="B119-ijms-24-01891" ref-type="bibr">119</xref>,<xref rid="B120-ijms-24-01891" ref-type="bibr">120</xref>,<xref rid="B121-ijms-24-01891" ref-type="bibr">121</xref>]. The activated p53 acts as a transcription factor, promoting the expression of several genes, from which we selected Tumor Protein P53 Inducible Nuclear Protein 1 (TP53INP1) as the most relevant in TRS for two reasons: (i) it has been the only one targeted by two of the miRNAs of the TRS profile (<xref rid="ijms-24-01891-f003" ref-type="fig">Figure 3</xref>) and (ii) the known interactions of its product and several GABA Type A Receptor-Associated Proteins (GABARAP, GABARAPL1/L2) [<xref rid="B122-ijms-24-01891" ref-type="bibr">122</xref>,<xref rid="B123-ijms-24-01891" ref-type="bibr">123</xref>,<xref rid="B124-ijms-24-01891" ref-type="bibr">124</xref>], which are known to mediate GABA-A receptor intracellular transport [<xref rid="B125-ijms-24-01891" ref-type="bibr">125</xref>,<xref rid="B126-ijms-24-01891" ref-type="bibr">126</xref>]. The availability of these GABA-A receptors has been related to the severity of symptoms in schizophrenia [<xref rid="B127-ijms-24-01891" ref-type="bibr">127</xref>], and elevated levels of its ligand GABA had been reported in the midcingulate cortex in TRS patients [<xref rid="B128-ijms-24-01891" ref-type="bibr">128</xref>]. In MNR, TP53INP1 is potentially targeted by two miRNAs of the TRS profile (<xref rid="ijms-24-01891-f003" ref-type="fig">Figure 3</xref>), one overexpressed (hsa-miR-504-5p) and one downregulated (hsa-miR-30b-5p).</p>
      <p>Although there is not much research about the role of p53 in TRS, there is some evidence linking alterations of p53 expression, its activation, and polymorphisms in TP53 with higher schizophrenia risk and symptoms severity [<xref rid="B97-ijms-24-01891" ref-type="bibr">97</xref>,<xref rid="B98-ijms-24-01891" ref-type="bibr">98</xref>,<xref rid="B129-ijms-24-01891" ref-type="bibr">129</xref>,<xref rid="B130-ijms-24-01891" ref-type="bibr">130</xref>,<xref rid="B131-ijms-24-01891" ref-type="bibr">131</xref>,<xref rid="B132-ijms-24-01891" ref-type="bibr">132</xref>]. Decreased levels of SIRT1 in plasma has been linked with a higher comorbidity of depressive symptoms [<xref rid="B133-ijms-24-01891" ref-type="bibr">133</xref>,<xref rid="B134-ijms-24-01891" ref-type="bibr">134</xref>,<xref rid="B135-ijms-24-01891" ref-type="bibr">135</xref>], whereas increased levels of DNMT1 had been observed in the brains of schizophrenia and bipolar patients [<xref rid="B136-ijms-24-01891" ref-type="bibr">136</xref>,<xref rid="B137-ijms-24-01891" ref-type="bibr">137</xref>,<xref rid="B138-ijms-24-01891" ref-type="bibr">138</xref>,<xref rid="B139-ijms-24-01891" ref-type="bibr">139</xref>]. Finally, MDM2 had been found to be underexpressed in the dorsolateral prefrontal cortex of schizophrenia patients [<xref rid="B96-ijms-24-01891" ref-type="bibr">96</xref>].</p>
      <p>All this together points to an atypical response to stress after antipsychotic administration as one key factor in the development of antipsychotic resistance. Our results indicate that this response could be potentially mediated by p53, with an important implication of its regulators MDM2, TRIM28, SIRT1, and DNMT1. Future research on TRS might focus on comparing the expression of these molecules between TRS and non-TRS patients.</p>
    </sec>
    <sec id="sec3dot6-ijms-24-01891">
      <title>3.6. Limitations and Future Perspectives</title>
      <p>This study has the following limitations. (i) Despite the fact that we defined a TRS fingerprint based on the miRNA differential expression between MR and MNR groups, the mechanism through which those miRNAs affect the resistance condition is still unknown. (ii) Whether peripheral miRNAs represent changes in the central nervous system was not assessed. Further experiments analysing cerebral spinal fluid in human samples might be an interesting approach. (iii) Although we corrected for processing batch; sex; drug consumption; time; treatment based on the subgroup of the diazepines, oxazepines, thiazepines, and oxepins; and treatment based on other antipsychotics, it could have been of interest to also correct for treatments based on clozapine and the presence of cognitive decline. (iv) It might have been interesting to study the miRNA response to specific antipsychotic therapies. (v) Results of the hierarchical clustering suggest that the TRS profile is partially associated with the schizophrenia condition, not only with antipsychotic resistance. (vi) The sample size is modest; therefore, it is difficult to predict the scope of our conclusions. It would be necessary to assess the expression of the TRS profile in an independent sample of patients. (vii) At the time of writing this paper, four miRNAs, namely, hsa-miR-548ac, hsa-miR-548ay-3p, hsa-miR-660-5p, and hsa-miR-6747-3p, did not have any predicted target in the last version of Tarbase v.8. Therefore, our functional analysis and the conclusions drawn from it are based on 12 of the 16 miRNAs of the TRS profile. It would be interesting to repeat the functional analysis in the near future.</p>
    </sec>
  </sec>
  <sec id="sec4-ijms-24-01891">
    <title>4. Materials and Methods</title>
    <sec id="sec4dot1-ijms-24-01891">
      <title>4.1. Experimental Design</title>
      <p>We recruited schizophrenia patients with a normal antipsychotic response (MR; <italic toggle="yes">n</italic> = 19), schizophrenia patients with antipsychotic resistance (MNR; <italic toggle="yes">n</italic> = 21), patients with a first psychotic episode (P; <italic toggle="yes">n</italic> = 13), and 43 healthy individuals (C; <italic toggle="yes">n</italic> = 43). Two blood samples were collected per patient, the first one at the hospital arrival (MRA, MNRA, PA) and the second one at the hospital discharge (MRD, MNRD, PD). Scores on PANSS (positive, negative, general) and SAAS scales were recorded at the arrival [<xref rid="B140-ijms-24-01891" ref-type="bibr">140</xref>,<xref rid="B141-ijms-24-01891" ref-type="bibr">141</xref>]. P patients were followed up until they could be classified as responders or nonresponders to medication, resulting in eight PA with normal antipsychotic response (PA<sub>R</sub> = 9) and four PA with antipsychotic resistance (PA<sub>NR</sub> = 4). As treatment resistance is a chronic condition in schizophrenia, and environmental changes during hospital admission can disturb miRNA expression, we will consider arrival and discharge samples from the same patient as two replicas of the same condition. Thus, differences between the MR and MNR groups will be more likely to be related with TRS and not with environmental variations. From now on, we will use MR to refer to MRA and MRD samples and MNR to refer to MNRA and MNRD samples.</p>
      <p>To find a miRNA signature of the antipsychotic response, we looked for differences in miRNA expression between the MR and MNR groups. The resulting “miRNA signature” was used to perform a hierarchical clustering with the MR, MNR, and PA samples; we are interested in the clusters assigned to PA samples, as well as the overall distribution of groups between clusters. As a first approach to outline the biological context of these results, we performed a target prediction, followed by a network and a functional analysis of the miRNAs of the signature.</p>
    </sec>
    <sec sec-type="subjects" id="sec4dot2-ijms-24-01891">
      <title>4.2. Human Participants Included in the Study</title>
      <p>Patients were recruited from Álvaro Cunqueiro Hospital (Vigo, Spain) between September 2018 and November 2021. Inclusion criteria were: (i) meeting the DSM-V schizophrenia diagnostic criteria, (ii) aged 18 years or older, and (iii) signed written consent. The exclusion criteria were an additional DSM-V diagnosis, medical illnesses, and neurological conditions, as well as pregnancy or lactation. Age, sex, drug consumption (alcohol/tobacco/illegal), and current pharmacological treatment were recorded for each patient (<xref rid="ijms-24-01891-t003" ref-type="table">Table 3</xref>).</p>
      <p>All patients and controls for this study were of Spanish nationality. The research was conducted in accordance with the Declaration of Helsinki, and all relevant ethical approvals were obtained. Written consent was obtained from all patients or their corresponding legal guardians.</p>
    </sec>
    <sec id="sec4dot3-ijms-24-01891">
      <title>4.3. Blood Collection</title>
      <p>Two blood samples per patient were drawn from the cubital vein and collected into PAXgene tubes (BD Biosciences, Franklin Lakes, NJ, USA) in the morning between 8 and 10 a.m, the first one at the hospital arrival and the second one at the hospital discharge. Samples were incubated 2 h at room temperature to ensure complete lysis of blood cells. PAXgene tubes were stored in the freezer (−80 °C) following commercial specifications (Qiagen, Hilden, Germany). The tubes were first transferred to −20 °C (24–72 h) and then transferred to −80 °C freezer until further processing.</p>
    </sec>
    <sec id="sec4dot4-ijms-24-01891">
      <title>4.4. Total RNA Purification from Human Blood Samples</title>
      <p>Total RNA, including small RNA, was purified from whole blood samples using the PAXgene<sup>®</sup> Blood microRNA Kit from Qiagen (PreAnalytiX GmbH, Hombrechtikon, Switzerland). PAXgene Blood microRNA Kit isolates total RNA &gt;18 nucleotides (including miRNA) from human whole blood. Before isolation, samples were put at room temperature overnight. We used Automated purification of total RNA, including miRNA, on QIAcube instruments, following the manual specification (Qiagen, Hilden, Germany). Briefly, tubes were centrifuged for 10 min at 4000× <italic toggle="yes">g</italic>, and supernatant was removed. A total of 4 mL of RNAse-free water was added to the pellet and then vortexed until the pellet was visibly dissolved. After that, ten minutes of centrifugation at 4000× <italic toggle="yes">g</italic> were applied. This step was repeated once more. After that, pellet was resuspended in buffer BM1, transferred to the 2 mL processing tube, and loaded into the QIAcube Connect shaker. Proteinase K and Buffer BM2 were added prior to the 10 min period of incubation at 55 °C. Incubated tubes were transferred to PAXgene Shredder Spin Column, where 3 min of centrifugation at full speed was applied. Supernatant was transferred into new tubes, and isopropanol was added. Samples were loaded on PAXgene RNA spin columns that bind total RNA &gt;18 nucleotides (including miRNA). Centrifugation at 10,000× <italic toggle="yes">g</italic> for 1 min was applied. Samples were washed once for 15 s with buffer BM3 and centrifuged at 10,000× <italic toggle="yes">g</italic> for 1 min. A DNA digestion was performed by incubating samples with DNase solution for 15 min at room temperature, followed by a centrifugation at 10,000× <italic toggle="yes">g</italic> for 1 min. Spin columns were washed, first with Buffer BM3 and then with Buffer BM4, at 10,000× <italic toggle="yes">g</italic> for 2 min each. Samples were eluted with 50 µL of BR5 Buffer to microcentrifuge tubes. One minute of centrifugation at 10,000× <italic toggle="yes">g</italic> was applied prior to the sample incubation at 65 °C for 5 min in the QIAcube Connect shaker. Finally, samples were immediately transferred to ice after incubation and then stored at −80 °C until further use.</p>
    </sec>
    <sec id="sec4dot5-ijms-24-01891">
      <title>4.5. Small RNA Sequencing</title>
      <p>For RNA quality control, a Bioanalyzer Instrument (Agilent Technologies, Santa Clara, CA, USA) was used. For concentration determination, a NanoDrop (Thermo Scientific, Waltham, MA, USA) was used. In addition, for evaluating RNA sample quality prior to miRNA/small RNA NGS library preparation, a QIAseq miRNA Library QC Spike-ins kit was used (Qiagen, Hilden, Germany). Library preparation was done using NEBNext Multiplex Small RNA Sample Prep Set for illumina (New England biolabs, Ipswich, MA, USA) to produce high quality microRNAome data from human blood samples. Briefly, the total amount of 150 ng of RNA was taken for further cDNA preparation, fragmentation, adapter ligation, and hybridization. After pooling the libraries together, polyacrylamide gel electrophoresis was run for size selection. The insert size of 150 base pairs (bp) was chosen for quantification and purification. Quality was checked on Bioanalyzer Instrument, and libraries were quantified using a Qubit 2.0 Fluorometer (Life Technologies, Carlsbad, CA, USA). Sequencing of 8 pM concentration was performed on HiSeq 2000 sequencing system (Illumina, San Diego, CA, USA) using a 24 samples per Lane, 50 bp single read setup. As a control for Illumina sequencing runs, a PhiX Control that is a reliable adapter-ligated library was used. Sequencing data were demultiplexed using CASAVA v1.8 (Illumina, San Diego, CA, USA), and raw fastq files were generated.</p>
    </sec>
    <sec id="sec4dot6-ijms-24-01891">
      <title>4.6. Bioinformatics Analysis</title>
      <p>The analytical methodology is detailed in <xref rid="app1-ijms-24-01891" ref-type="app">Supplementary Figure S1</xref>. For quality control of the raw data, adapter removal, alignment, and quantification, we used the software myBrain-Seq v0.1.0 [<xref rid="B23-ijms-24-01891" ref-type="bibr">23</xref>]. The biological references used were the GRCh38 human genomic build [<xref rid="B142-ijms-24-01891" ref-type="bibr">142</xref>] for the alignment and miRBase v.22 database [<xref rid="B143-ijms-24-01891" ref-type="bibr">143</xref>] for the miRNA annotation. We filtered miRNAs with less than 10 counts in total using a custom R script. Differential expression analyses were performed using DESeq2 v1.32.0 [<xref rid="B144-ijms-24-01891" ref-type="bibr">144</xref>], adapting the script of myBrain-Seq to adjust for six potential confounding variables: (i) processing batch, (ii) sex, (iii) drug consumption (alcohol OR tobacco OR illegal), (iv) time (arrival, discharge), (v) treatment based in the subgroup of the diazepines, oxazepines, thiazepines, and oxepins, and (vi) treatment based in other antipsychotics. To obtain a miRNA signature for the resistance to medication, we first performed the DEA comparing MR vs. MNR, then subtracted from this profile the common miRNAs between DEA comparisons MNR vs. C and MR vs. C. This was done to filter miRNAs with potentially similar roles in MR and MNR conditions and to obtain the “miRNA profile” (<xref rid="app1-ijms-24-01891" ref-type="app">Supplementary Figure S1</xref>, point 3).</p>
    </sec>
    <sec id="sec4dot7-ijms-24-01891">
      <title>4.7. Hierarchical Clustering</title>
      <p>We performed two different hierarchical clustering analyses using the miRNAs found in the “miRNA profile”: the first one with MR and MNR samples, the second one with MR, MNR, and PA samples. Prior to the hierarchical clustering, the miRNA counts of the profiles were normalised using the Relative Log Expression method of DESeq2 1.32.0 [<xref rid="B144-ijms-24-01891" ref-type="bibr">144</xref>]. We used the R package hclust [<xref rid="B24-ijms-24-01891" ref-type="bibr">24</xref>] for clustering, using the Euclidean distance metric and Ward method (ward.D2).</p>
    </sec>
    <sec id="sec4dot8-ijms-24-01891">
      <title>4.8. Functional Analysis</title>
      <p>To narrow down the potential implication of the differentially expressed miRNAs on the antipsychotic resistance, we conducted a target prediction analysis, bibliographic search, and network analysis. For the prediction of the miRNA targets, we used TarBase v8 [<xref rid="B27-ijms-24-01891" ref-type="bibr">27</xref>] and a custom bash script. The bibliographic search was performed in order to add documented targets not present in TarBase v8; we looked for genes related to chemoresistance or the metabolism of antipsychotics, or those involved in the diffusion of molecules through the blood–brain barrier. To perform the network analysis, we used Cytoscape 3.9.1 [<xref rid="B25-ijms-24-01891" ref-type="bibr">25</xref>]. We started by importing the miRNA–gene interactions obtained from TarBase v8 and the literature search. Then, we selected the miRNAs and ran the Cytoscape default heat diffusion algorithm [<xref rid="B145-ijms-24-01891" ref-type="bibr">145</xref>]. Selected nodes were used as a query in the Uniprot database [<xref rid="B146-ijms-24-01891" ref-type="bibr">146</xref>], and the resulting networks were merged with the miRNA–gene network. Finally, we used StringApp 2.0.0 [<xref rid="B26-ijms-24-01891" ref-type="bibr">26</xref>] to annotate proteins, to filter by tissue, and to perform the functional enrichment analysis of pathways. We kept proteins expressed only in the category of “nervous system” with a tissue score of 4.50 and in the category of “blood” with a tissue score of 3.00. For the pathway enrichment analysis, we used Reactome Pathways [<xref rid="B147-ijms-24-01891" ref-type="bibr">147</xref>], WikiPathways [<xref rid="B148-ijms-24-01891" ref-type="bibr">148</xref>], and KEGG [<xref rid="B62-ijms-24-01891" ref-type="bibr">62</xref>] Pathways databases. To find highly connected subnetworks, we applied a degree filter of value 10.</p>
    </sec>
  </sec>
  <sec sec-type="conclusions" id="sec5-ijms-24-01891">
    <title>5. Conclusions</title>
    <p>We presented a 16-miRNA profile related to treatment-resistant schizophrenia. With this profile, we performed a hierarchical clustering of MR and MNR samples that resulted in two clusters: the first one with 73.2% of the MR samples and the second one with 72.4% of the MNR samples. We did not use the PANSS and SAAS scores to improve the clustering accuracy, as we did not find associations between PANSS and SAAS scores and the TRS condition. By observing the dendrogram of MR, MNR, and PA samples, we deduced that similarities between the TRS profile of patients with a first psychotic episode and schizophrenia patients’ response to medication seem to be potential evidence of a first psychotic episode unrelated to schizophrenia. The network and functional analysis of the TRS profile suggests that atypical response to stress after antipsychotic administration could be one key factor in the development of antipsychotic resistance. Finally, we condensed all the results in a molecular pathway that is presumably altered in TRS patients, with a pivotal role of p53 and its regulators MDM2, TRIM28, SIRT1, DNMT1, and eight miRNAs of the TRS profile.</p>
  </sec>
</body>
<back>
  <ack>
    <title>Acknowledgments</title>
    <p><xref rid="ijms-24-01891-f003" ref-type="fig">Figure 3</xref> was created with BioRender.com. The authors would like to thank Galicia Sur Health Research Institute and the Área Sanitaria de Vigo for their support. We specially thank the Psychiatric Nursing Service and psychiatrists at the Álvaro Cunqueiro Hospital and Nicolás Peña Hospital. Finally, we acknowledge Estela Portillo Encina (ADHD Children’s Organization, ANHIDA), José Luis Fernández Sastre (Psychiatry Department, University Hospital of Vigo), and Maria Tereixa Brañas Pérez (Family medicine, SERGAS) for their intellectual and motivational help in the development of this work.</p>
  </ack>
  <fn-group>
    <fn>
      <p><bold>Disclaimer/Publisher’s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p>
    </fn>
  </fn-group>
  <app-group>
    <app id="app1-ijms-24-01891">
      <title>Supplementary Materials</title>
      <p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/ijms24031891/s1">https://www.mdpi.com/article/10.3390/ijms24031891/s1</uri>.</p>
      <supplementary-material id="ijms-24-01891-s001" position="float" content-type="local-data">
        <media xlink:href="ijms-24-01891-s001.zip">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </app>
  </app-group>
  <notes>
    <title>Author Contributions</title>
    <p>Conceptualization, D.P.-R., H.L.-F. and R.C.A.-B.; Methodology, D.P.-R., M.A.P., T.R.-B., S.B., A.F., J.M.O., H.L.-F. and R.C.A.-B.; Software, D.P.-R., H.L.-F. and R.C.A.-B.; Formal Analysis, D.P.-R. and T.P.-C.; Investigation, D.P.-R., M.A.P., T.R.-B., J.M.O., H.L.-F. and R.C.A.-B.; Resources, J.M.O. and R.C.A.-B.; Data Curation, D.P.-R., M.A.P., T.R.-B., T.P.-C., J.M.P.-G., J.M.O., H.L.-F. and R.C.A.-B.; Writing—Original Draft Preparation, D.P.-R., H.L.-F. and R.C.A.-B.; Writing—Review &amp; Editing, D.P.-R., M.A.P., T.R.-B., T.P.-C., S.B., A.F., J.M.P.-G., J.M.O., H.L.-F. and R.C.A.-B.; Visualization, D.P.-R.; Supervision, H.L.-F. and R.C.A.-B.; Project Administration, D.P.-R., H.L.-F. and R.C.A.-B.; Funding Acquisition, R.C.A.-B. All authors have read and agreed to the published version of the manuscript.</p>
  </notes>
  <notes>
    <title>Institutional Review Board Statement</title>
    <p>The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of Galicia Sur Health Research Institute (IIS Galicia Sur) (protocol code 2016/577, 2 March 2017).</p>
  </notes>
  <notes>
    <title>Informed Consent Statement</title>
    <p>Informed consent was obtained from all subjects involved in the study.</p>
  </notes>
  <notes notes-type="data-availability">
    <title>Data Availability Statement</title>
    <p>Data accessible at NCBI GEO database, accession GSE223043 (<uri xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE223043">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE223043</uri>).</p>
  </notes>
  <notes notes-type="COI-statement">
    <title>Conflicts of Interest</title>
    <p>The authors declare no conflict of interest.</p>
  </notes>
  <ref-list>
    <title>References</title>
    <ref id="B1-ijms-24-01891">
      <label>1.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Saha</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Chant</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Welham</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>McGrath</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>A Systematic Review of the Prevalence of Schizophrenia</article-title>
        <source>PLoS Med.</source>
        <year>2005</year>
        <volume>2</volume>
        <elocation-id>e141</elocation-id>
        <pub-id pub-id-type="doi">10.1371/journal.pmed.0020141</pub-id>
        <?supplied-pmid 15916472?>
        <pub-id pub-id-type="pmid">15916472</pub-id>
      </element-citation>
    </ref>
    <ref id="B2-ijms-24-01891">
      <label>2.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Elkis</surname>
            <given-names>H.</given-names>
          </name>
        </person-group>
        <article-title>Treatment-Resistant Schizophrenia</article-title>
        <source>Psychiatr. Clin. N. Am.</source>
        <year>2007</year>
        <volume>30</volume>
        <fpage>511</fpage>
        <lpage>533</lpage>
        <pub-id pub-id-type="doi">10.1016/j.psc.2007.04.001</pub-id>
        <?supplied-pmid 17720034?>
        <pub-id pub-id-type="pmid">17720034</pub-id>
      </element-citation>
    </ref>
    <ref id="B3-ijms-24-01891">
      <label>3.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Essock</surname>
            <given-names>S.M.</given-names>
          </name>
          <name>
            <surname>Hargreaves</surname>
            <given-names>W.A.</given-names>
          </name>
          <name>
            <surname>Covell</surname>
            <given-names>N.H.</given-names>
          </name>
          <name>
            <surname>Goethe</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>Clozapine’s Effectiveness for Patients in State Hospitals: Results from a Randomized Trial</article-title>
        <source>Psychopharmacol. Bull.</source>
        <year>1996</year>
        <volume>32</volume>
        <fpage>683</fpage>
        <lpage>697</lpage>
        <?supplied-pmid 8993092?>
        <pub-id pub-id-type="pmid">8993092</pub-id>
      </element-citation>
    </ref>
    <ref id="B4-ijms-24-01891">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lieberman</surname>
            <given-names>J.A.</given-names>
          </name>
        </person-group>
        <article-title>Pathophysiologic Mechanisms in the Pathogenesis and Clinical Course of Schizophrenia</article-title>
        <source>J. Clin. Psychiatr.</source>
        <year>1999</year>
        <volume>12</volume>
        <fpage>9</fpage>
        <lpage>12</lpage>
      </element-citation>
    </ref>
    <ref id="B5-ijms-24-01891">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lindenmayer</surname>
            <given-names>J.P.</given-names>
          </name>
        </person-group>
        <article-title>Treatment Refractory Schizophrenia</article-title>
        <source>Psychiatr. Q.</source>
        <year>2000</year>
        <volume>71</volume>
        <fpage>373</fpage>
        <lpage>384</lpage>
        <pub-id pub-id-type="doi">10.1023/A:1004640408501</pub-id>
        <pub-id pub-id-type="pmid">11025914</pub-id>
      </element-citation>
    </ref>
    <ref id="B6-ijms-24-01891">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Correll</surname>
            <given-names>C.U.</given-names>
          </name>
          <name>
            <surname>Howes</surname>
            <given-names>O.D.</given-names>
          </name>
        </person-group>
        <article-title>Treatment-Resistant Schizophrenia: Definition, Predictors, and Therapy Options</article-title>
        <source>J. Clin. Psychiatr.</source>
        <year>2021</year>
        <volume>82</volume>
        <fpage>36608</fpage>
        <pub-id pub-id-type="doi">10.4088/JCP.MY20096AH1C</pub-id>
      </element-citation>
    </ref>
    <ref id="B7-ijms-24-01891">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kennedy</surname>
            <given-names>J.L.</given-names>
          </name>
          <name>
            <surname>Altar</surname>
            <given-names>C.A.</given-names>
          </name>
          <name>
            <surname>Taylor</surname>
            <given-names>D.L.</given-names>
          </name>
          <name>
            <surname>Degtiar</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Hornberger</surname>
            <given-names>J.C.</given-names>
          </name>
        </person-group>
        <article-title>The Social and Economic Burden of Treatment-Resistant Schizophrenia: A Systematic Literature Review</article-title>
        <source>Int. Clin. Psychopharmacol.</source>
        <year>2014</year>
        <volume>29</volume>
        <fpage>63</fpage>
        <lpage>76</lpage>
        <pub-id pub-id-type="doi">10.1097/YIC.0b013e32836508e6</pub-id>
        <pub-id pub-id-type="pmid">23995856</pub-id>
      </element-citation>
    </ref>
    <ref id="B8-ijms-24-01891">
      <label>8.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Millgate</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Kravariti</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>MacCabe</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Hide</surname>
            <given-names>O.</given-names>
          </name>
        </person-group>
        <article-title>S62. Cognitive deficits in treatment resistant schizophrenia</article-title>
        <source>Schizophr. Bull.</source>
        <year>2020</year>
        <volume>46</volume>
        <fpage>S56</fpage>
        <lpage>S57</lpage>
        <pub-id pub-id-type="doi">10.1093/schbul/sbaa031.128</pub-id>
      </element-citation>
    </ref>
    <ref id="B9-ijms-24-01891">
      <label>9.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fernández-Pereira</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Penedo</surname>
            <given-names>M.A.</given-names>
          </name>
          <name>
            <surname>Rivera-Baltanas</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Fernández-Martínez</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Ortolano</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Olivares</surname>
            <given-names>J.M.</given-names>
          </name>
          <name>
            <surname>Agís-Balboa</surname>
            <given-names>R.C.</given-names>
          </name>
        </person-group>
        <article-title>Insulin-like Growth Factor 2 (IGF-2) and Insulin-like Growth Factor Binding Protein 7 (IGFBP-7) Are Upregulated after Atypical Antipsychotics in Spanish Schizophrenia Patients</article-title>
        <source>Int. J. Mol. Sci.</source>
        <year>2022</year>
        <volume>23</volume>
        <elocation-id>9591</elocation-id>
        <pub-id pub-id-type="doi">10.3390/ijms23179591</pub-id>
        <pub-id pub-id-type="pmid">36076984</pub-id>
      </element-citation>
    </ref>
    <ref id="B10-ijms-24-01891">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Correll</surname>
            <given-names>C.U.</given-names>
          </name>
          <name>
            <surname>Brevig</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Brain</surname>
            <given-names>C.</given-names>
          </name>
        </person-group>
        <article-title>Patient Characteristics, Burden and Pharmacotherapy of Treatment-Resistant Schizophrenia: Results from a Survey of 204 US Psychiatrists</article-title>
        <source>BMC Psychiatr.</source>
        <year>2019</year>
        <volume>19</volume>
        <elocation-id>362</elocation-id>
        <pub-id pub-id-type="doi">10.1186/s12888-019-2318-x</pub-id>
      </element-citation>
    </ref>
    <ref id="B11-ijms-24-01891">
      <label>11.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ballon</surname>
            <given-names>J.S.</given-names>
          </name>
          <name>
            <surname>Lieberman</surname>
            <given-names>J.A.</given-names>
          </name>
        </person-group>
        <article-title>Advances in the Management of Treatment- Resistant Schizophrenia</article-title>
        <source>FOC</source>
        <year>2010</year>
        <volume>8</volume>
        <fpage>475</fpage>
        <lpage>487</lpage>
        <pub-id pub-id-type="doi">10.1176/foc.8.4.foc475</pub-id>
      </element-citation>
    </ref>
    <ref id="B12-ijms-24-01891">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Englisch</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Zink</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>Treatment-Resistant Schizophrenia: Evidence-Based Strategies</article-title>
        <source>Mens Sana Monogr.</source>
        <year>2012</year>
        <volume>10</volume>
        <fpage>20</fpage>
        <lpage>32</lpage>
        <pub-id pub-id-type="doi">10.4103/0973-1229.91588</pub-id>
        <?supplied-pmid 22654380?>
        <pub-id pub-id-type="pmid">22654380</pub-id>
      </element-citation>
    </ref>
    <ref id="B13-ijms-24-01891">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sinclair</surname>
            <given-names>D.J.</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Qi</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Nyakyoma</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Kwong</surname>
            <given-names>J.S.</given-names>
          </name>
          <name>
            <surname>Adams</surname>
            <given-names>C.E.</given-names>
          </name>
        </person-group>
        <article-title>Electroconvulsive Therapy for Treatment-Resistant Schizophrenia</article-title>
        <source>Cochrane Database Syst. Rev.</source>
        <year>2019</year>
        <volume>3</volume>
        <fpage>CD011847</fpage>
        <pub-id pub-id-type="doi">10.1002/14651858.CD011847.pub2</pub-id>
        <pub-id pub-id-type="pmid">30888709</pub-id>
      </element-citation>
    </ref>
    <ref id="B14-ijms-24-01891">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kane</surname>
            <given-names>J.M.</given-names>
          </name>
          <name>
            <surname>Kishimoto</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Correll</surname>
            <given-names>C.U.</given-names>
          </name>
        </person-group>
        <article-title>Non-Adherence to Medication in Patients with Psychotic Disorders: Epidemiology, Contributing Factors and Management Strategies</article-title>
        <source>World Psychiatr.</source>
        <year>2013</year>
        <volume>12</volume>
        <fpage>216</fpage>
        <lpage>226</lpage>
        <pub-id pub-id-type="doi">10.1002/wps.20060</pub-id>
        <?supplied-pmid 24096780?>
        <pub-id pub-id-type="pmid">24096780</pub-id>
      </element-citation>
    </ref>
    <ref id="B15-ijms-24-01891">
      <label>15.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Nucifora</surname>
            <given-names>F.C.</given-names>
          </name>
          <name>
            <surname>Woznica</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>B.J.</given-names>
          </name>
          <name>
            <surname>Cascella</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Sawa</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>Treatment Resistant Schizophrenia: Clinical, Biological, and Therapeutic Perspectives</article-title>
        <source>Neurobiol. Dis.</source>
        <year>2019</year>
        <volume>131</volume>
        <fpage>104257</fpage>
        <pub-id pub-id-type="doi">10.1016/j.nbd.2018.08.016</pub-id>
        <?supplied-pmid 30170114?>
        <pub-id pub-id-type="pmid">30170114</pub-id>
      </element-citation>
    </ref>
    <ref id="B16-ijms-24-01891">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pérez-Rodríguez</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>López-Fernández</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Agís-Balboa</surname>
            <given-names>R.C.</given-names>
          </name>
        </person-group>
        <article-title>Application of MiRNA-Seq in Neuropsychiatry: A Methodological Perspective</article-title>
        <source>Comput. Biol. Med.</source>
        <year>2021</year>
        <volume>135</volume>
        <fpage>31</fpage>
        <lpage>42</lpage>
        <pub-id pub-id-type="doi">10.1016/j.compbiomed.2021.104603</pub-id>
      </element-citation>
    </ref>
    <ref id="B17-ijms-24-01891">
      <label>17.</label>
      <element-citation publication-type="confproc">
        <person-group person-group-type="author">
          <name>
            <surname>Pérez-Rodríguez</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>López-Fernández</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Agís-Balboa</surname>
            <given-names>R.C.</given-names>
          </name>
        </person-group>
        <article-title>On the Reproducibility of MiRNA-Seq Differential Expression Analyses in Neuropsychiatric Diseases</article-title>
        <source>Proceedings of the Practical Applications of Computational Biology &amp; Bioinformatics, 15th International Conference (PACBB 2021)</source>
        <conf-loc>Salamanca, Spain</conf-loc>
        <conf-date>6–8 October 2021</conf-date>
        <person-group person-group-type="editor">
          <name>
            <surname>Rocha</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Fdez-Riverola</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Mohamad</surname>
            <given-names>M.S.</given-names>
          </name>
          <name>
            <surname>Casado-Vara</surname>
            <given-names>R.</given-names>
          </name>
        </person-group>
        <publisher-name>Springer International Publishing</publisher-name>
        <publisher-loc>Cham, Switzerland</publisher-loc>
        <year>2022</year>
        <fpage>41</fpage>
        <lpage>51</lpage>
      </element-citation>
    </ref>
    <ref id="B18-ijms-24-01891">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pandey</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Kalita</surname>
            <given-names>K.N.</given-names>
          </name>
        </person-group>
        <article-title>Treatment-Resistant Schizophrenia: How Far Have We Traveled?</article-title>
        <source>Front. Psychiatr.</source>
        <year>2022</year>
        <volume>13</volume>
        <fpage>994425</fpage>
        <pub-id pub-id-type="doi">10.3389/fpsyt.2022.994425</pub-id>
      </element-citation>
    </ref>
    <ref id="B19-ijms-24-01891">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Potkin</surname>
            <given-names>S.G.</given-names>
          </name>
          <name>
            <surname>Kane</surname>
            <given-names>J.M.</given-names>
          </name>
          <name>
            <surname>Correll</surname>
            <given-names>C.U.</given-names>
          </name>
          <name>
            <surname>Lindenmayer</surname>
            <given-names>J.-P.</given-names>
          </name>
          <name>
            <surname>Agid</surname>
            <given-names>O.</given-names>
          </name>
          <name>
            <surname>Marder</surname>
            <given-names>S.R.</given-names>
          </name>
          <name>
            <surname>Olfson</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Howes</surname>
            <given-names>O.D.</given-names>
          </name>
        </person-group>
        <article-title>The Neurobiology of Treatment-Resistant Schizophrenia: Paths to Antipsychotic Resistance and a Roadmap for Future Research</article-title>
        <source>NPJ Schizophr.</source>
        <year>2020</year>
        <volume>6</volume>
        <fpage>1</fpage>
        <pub-id pub-id-type="doi">10.1038/s41537-019-0090-z</pub-id>
        <pub-id pub-id-type="pmid">31911624</pub-id>
      </element-citation>
    </ref>
    <ref id="B20-ijms-24-01891">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Delgado-Morales</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Agís-Balboa</surname>
            <given-names>R.C.</given-names>
          </name>
          <name>
            <surname>Esteller</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Berdasco</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>Epigenetic Mechanisms during Ageing and Neurogenesis as Novel Therapeutic Avenues in Human Brain Disorders</article-title>
        <source>Clin. Epigenet.</source>
        <year>2017</year>
        <volume>9</volume>
        <fpage>67</fpage>
        <pub-id pub-id-type="doi">10.1186/s13148-017-0365-z</pub-id>
        <?supplied-pmid 28670349?>
        <pub-id pub-id-type="pmid">28670349</pub-id>
      </element-citation>
    </ref>
    <ref id="B21-ijms-24-01891">
      <label>21.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Esteller</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>Non-Coding RNAs in Human Disease</article-title>
        <source>Nat. Rev. Genet.</source>
        <year>2011</year>
        <volume>12</volume>
        <fpage>861</fpage>
        <lpage>874</lpage>
        <pub-id pub-id-type="doi">10.1038/nrg3074</pub-id>
        <pub-id pub-id-type="pmid">22094949</pub-id>
      </element-citation>
    </ref>
    <ref id="B22-ijms-24-01891">
      <label>22.</label>
      <element-citation publication-type="confproc">
        <person-group person-group-type="author">
          <name>
            <surname>Pérez-Rodríguez</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Pérez-Rodríguez</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Agís-Balboa</surname>
            <given-names>R.C.</given-names>
          </name>
          <name>
            <surname>López-Fernández</surname>
            <given-names>H.</given-names>
          </name>
        </person-group>
        <article-title>Towards a Flexible and Portable Workflow for Analyzing MiRNA-Seq Neuropsychiatric Data: An Initial Replicability Assessment</article-title>
        <source>Proceedings of the Practical Applications of Computational Biology and Bioinformatics, 16th International Conference (PACBB 2022)</source>
        <conf-loc>L’Aquila, Italy</conf-loc>
        <conf-date>13–15 July 2022</conf-date>
        <person-group person-group-type="editor">
          <name>
            <surname>Fdez-Riverola</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Rocha</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Mohamad</surname>
            <given-names>M.S.</given-names>
          </name>
          <name>
            <surname>Caraiman</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Gil-González</surname>
            <given-names>A.B.</given-names>
          </name>
        </person-group>
        <publisher-name>Springer International Publishing</publisher-name>
        <publisher-loc>Cham, Switzerland</publisher-loc>
        <year>2023</year>
        <fpage>31</fpage>
        <lpage>42</lpage>
      </element-citation>
    </ref>
    <ref id="B23-ijms-24-01891">
      <label>23.</label>
      <element-citation publication-type="webpage">
        <person-group person-group-type="author">
          <name>
            <surname>Pérez-Rodríguez</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>López-Fernández</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Agís-Balboa</surname>
            <given-names>R.C.</given-names>
          </name>
        </person-group>
        <article-title>MyBrain-Seq</article-title>
        <year>2022</year>
        <comment>Available online: <ext-link xlink:href="https://github.com/sing-group/my-brain-seq" ext-link-type="uri">https://github.com/sing-group/my-brain-seq</ext-link></comment>
        <date-in-citation content-type="access-date" iso-8601-date="2022-06-10">(accessed on 10 June 2022)</date-in-citation>
      </element-citation>
    </ref>
    <ref id="B24-ijms-24-01891">
      <label>24.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <collab>R Core Team</collab>
        </person-group>
        <source>R: A Language and Environment for Statistical Computing</source>
        <publisher-name>R Foundation for Statistical Computing</publisher-name>
        <publisher-loc>Vienna, Austria</publisher-loc>
        <year>2013</year>
      </element-citation>
    </ref>
    <ref id="B25-ijms-24-01891">
      <label>25.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Shannon</surname>
            <given-names>P.</given-names>
          </name>
        </person-group>
        <article-title>Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks</article-title>
        <source>Genome Res.</source>
        <year>2003</year>
        <volume>13</volume>
        <fpage>2498</fpage>
        <lpage>2504</lpage>
        <pub-id pub-id-type="doi">10.1101/gr.1239303</pub-id>
        <?supplied-pmid 14597658?>
        <pub-id pub-id-type="pmid">14597658</pub-id>
      </element-citation>
    </ref>
    <ref id="B26-ijms-24-01891">
      <label>26.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Doncheva</surname>
            <given-names>N.T.</given-names>
          </name>
          <name>
            <surname>Morris</surname>
            <given-names>J.H.</given-names>
          </name>
          <name>
            <surname>Gorodkin</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Jensen</surname>
            <given-names>L.J.</given-names>
          </name>
        </person-group>
        <article-title>Cytoscape StringApp: Network Analysis and Visualization of Proteomics Data</article-title>
        <source>J. Proteome Res.</source>
        <year>2019</year>
        <volume>18</volume>
        <fpage>623</fpage>
        <lpage>632</lpage>
        <pub-id pub-id-type="doi">10.1021/acs.jproteome.8b00702</pub-id>
        <pub-id pub-id-type="pmid">30450911</pub-id>
      </element-citation>
    </ref>
    <ref id="B27-ijms-24-01891">
      <label>27.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Karagkouni</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Paraskevopoulou</surname>
            <given-names>M.D.</given-names>
          </name>
          <name>
            <surname>Chatzopoulos</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Vlachos</surname>
            <given-names>I.S.</given-names>
          </name>
          <name>
            <surname>Tastsoglou</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Kanellos</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Papadimitriou</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Kavakiotis</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Maniou</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Skoufos</surname>
            <given-names>G.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>DIANA-TarBase v8: A Decade-Long Collection of Experimentally Supported MiRNA–Gene Interactions</article-title>
        <source>Nucl. Acids Res.</source>
        <year>2018</year>
        <volume>46</volume>
        <fpage>D239</fpage>
        <lpage>D245</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkx1141</pub-id>
        <pub-id pub-id-type="pmid">29156006</pub-id>
      </element-citation>
    </ref>
    <ref id="B28-ijms-24-01891">
      <label>28.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Gao</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Ding</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Ding</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Jia</surname>
            <given-names>Z.</given-names>
          </name>
        </person-group>
        <article-title>Down-Regulation of MiR-210-3p Encourages Chemotherapy Resistance of Renal Cell Carcinoma via Modulating ABCC1</article-title>
        <source>Cell Biosci.</source>
        <year>2018</year>
        <volume>8</volume>
        <fpage>9</fpage>
        <pub-id pub-id-type="doi">10.1186/s13578-018-0209-3</pub-id>
        <?supplied-pmid 29445446?>
        <pub-id pub-id-type="pmid">29445446</pub-id>
      </element-citation>
    </ref>
    <ref id="B29-ijms-24-01891">
      <label>29.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sharma</surname>
            <given-names>A.R.</given-names>
          </name>
          <name>
            <surname>Vohra</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Shukla</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Guddattu</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Razak Uk</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Shetty</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Umakanth</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Satyamoorthy</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Rai</surname>
            <given-names>P.S.</given-names>
          </name>
        </person-group>
        <article-title>Coding SNPs in Hsa-MiR-1343-3p and Hsa-MiR-6783-3p Target Sites of CYP2C19 Modulates Clopidogrel Response in Individuals with Cardiovascular Diseases</article-title>
        <source>Life Sci.</source>
        <year>2020</year>
        <volume>245</volume>
        <fpage>117364</fpage>
        <pub-id pub-id-type="doi">10.1016/j.lfs.2020.117364</pub-id>
        <pub-id pub-id-type="pmid">32001263</pub-id>
      </element-citation>
    </ref>
    <ref id="B30-ijms-24-01891">
      <label>30.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lin</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Ren</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Jin</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>Human MicroRNA-30 Inhibits Influenza Virus Infection by Suppressing the Expression of SOCS1, SOCS3, and NEDD4</article-title>
        <source>Cell. Microbiol.</source>
        <year>2020</year>
        <volume>22</volume>
        <fpage>e13150</fpage>
        <pub-id pub-id-type="doi">10.1111/cmi.13150</pub-id>
        <pub-id pub-id-type="pmid">31876380</pub-id>
      </element-citation>
    </ref>
    <ref id="B31-ijms-24-01891">
      <label>31.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Duan</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Choy</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Harmon</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Susa</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Mankin</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Hornicek</surname>
            <given-names>F.</given-names>
          </name>
        </person-group>
        <article-title>MicroRNA-199a-3p Is Downregulated in Human Osteosarcoma and Regulates Cell Proliferation and Migration</article-title>
        <source>Mol. Cancer Ther.</source>
        <year>2011</year>
        <volume>10</volume>
        <fpage>1337</fpage>
        <lpage>1345</lpage>
        <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-11-0096</pub-id>
        <?supplied-pmid 21666078?>
        <pub-id pub-id-type="pmid">21666078</pub-id>
      </element-citation>
    </ref>
    <ref id="B32-ijms-24-01891">
      <label>32.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jiang</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Long</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Xie</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Kuang</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>MiR-500a-3p Promotes Cancer Stem Cells Properties via STAT3 Pathway in Human Hepatocellular Carcinoma</article-title>
        <source>J. Exp. Clin. Cancer Res.</source>
        <year>2017</year>
        <volume>36</volume>
        <fpage>99</fpage>
        <pub-id pub-id-type="doi">10.1186/s13046-017-0568-3</pub-id>
        <pub-id pub-id-type="pmid">28750679</pub-id>
      </element-citation>
    </ref>
    <ref id="B33-ijms-24-01891">
      <label>33.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Meng</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>Q.-M.</given-names>
          </name>
        </person-group>
        <article-title>LINC00319-Mediated MiR-3127 Repression Enhances Bladder Cancer Progression Through Upregulation of RAP2A</article-title>
        <source>Front. Genet.</source>
        <year>2020</year>
        <volume>11</volume>
        <fpage>180</fpage>
        <pub-id pub-id-type="doi">10.3389/fgene.2020.00180</pub-id>
        <?supplied-pmid 32194636?>
        <pub-id pub-id-type="pmid">32194636</pub-id>
      </element-citation>
    </ref>
    <ref id="B34-ijms-24-01891">
      <label>34.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Huerta-Zavala</surname>
            <given-names>M.L.</given-names>
          </name>
          <name>
            <surname>Lopez-Castillejos</surname>
            <given-names>E.S.</given-names>
          </name>
          <name>
            <surname>Requenez-Contreras</surname>
            <given-names>J.L.</given-names>
          </name>
          <name>
            <surname>Granados-Riveron</surname>
            <given-names>J.T.</given-names>
          </name>
          <name>
            <surname>Aquino-Jarquin</surname>
            <given-names>G.</given-names>
          </name>
        </person-group>
        <article-title>A Single MiRNA and MiRNA Sponge Expression System for Efficient Modulation of MiR-223 Availability in Mammalian Cells</article-title>
        <source>J. Gene Med.</source>
        <year>2019</year>
        <volume>21</volume>
        <fpage>e3100</fpage>
        <pub-id pub-id-type="doi">10.1002/jgm.3100</pub-id>
        <pub-id pub-id-type="pmid">31166636</pub-id>
      </element-citation>
    </ref>
    <ref id="B35-ijms-24-01891">
      <label>35.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Reinke</surname>
            <given-names>A.W.</given-names>
          </name>
          <name>
            <surname>Baek</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Ashenberg</surname>
            <given-names>O.</given-names>
          </name>
          <name>
            <surname>Keating</surname>
            <given-names>A.E.</given-names>
          </name>
        </person-group>
        <article-title>Networks of BZIP Protein-Protein Interactions Diversified over a Billion Years of Evolution</article-title>
        <source>Science</source>
        <year>2013</year>
        <volume>340</volume>
        <fpage>730</fpage>
        <lpage>734</lpage>
        <pub-id pub-id-type="doi">10.1126/science.1233465</pub-id>
        <?supplied-pmid 23661758?>
        <pub-id pub-id-type="pmid">23661758</pub-id>
      </element-citation>
    </ref>
    <ref id="B36-ijms-24-01891">
      <label>36.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Iacobelli</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Wachsman</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>McGuire</surname>
            <given-names>K.L.</given-names>
          </name>
        </person-group>
        <article-title>Repression of IL-2 Promoter Activity by the Novel Basic Leucine Zipper P21SNFT Protein1 2</article-title>
        <source>J. Immunol.</source>
        <year>2000</year>
        <volume>165</volume>
        <fpage>860</fpage>
        <lpage>868</lpage>
        <pub-id pub-id-type="doi">10.4049/jimmunol.165.2.860</pub-id>
        <?supplied-pmid 10878360?>
        <pub-id pub-id-type="pmid">10878360</pub-id>
      </element-citation>
    </ref>
    <ref id="B37-ijms-24-01891">
      <label>37.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bower</surname>
            <given-names>K.E.</given-names>
          </name>
          <name>
            <surname>Zeller</surname>
            <given-names>R.W.</given-names>
          </name>
          <name>
            <surname>Wachsman</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Martinez</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>McGuire</surname>
            <given-names>K.L.</given-names>
          </name>
        </person-group>
        <article-title>Correlation of Transcriptional Repression by P21SNFTwith Changes in DNA·NF-AT Complex Interactions</article-title>
        <source>J. Biol. Chem.</source>
        <year>2002</year>
        <volume>277</volume>
        <fpage>34967</fpage>
        <lpage>34977</lpage>
        <pub-id pub-id-type="doi">10.1074/jbc.M205048200</pub-id>
        <?supplied-pmid 12087103?>
        <pub-id pub-id-type="pmid">12087103</pub-id>
      </element-citation>
    </ref>
    <ref id="B38-ijms-24-01891">
      <label>38.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rodríguez-Martínez</surname>
            <given-names>J.A.</given-names>
          </name>
          <name>
            <surname>Reinke</surname>
            <given-names>A.W.</given-names>
          </name>
          <name>
            <surname>Bhimsaria</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Keating</surname>
            <given-names>A.E.</given-names>
          </name>
          <name>
            <surname>Ansari</surname>
            <given-names>A.Z.</given-names>
          </name>
        </person-group>
        <article-title>Combinatorial BZIP Dimers Display Complex DNA-Binding Specificity Landscapes</article-title>
        <source>eLife</source>
        <year>2017</year>
        <volume>6</volume>
        <fpage>e19272</fpage>
        <pub-id pub-id-type="doi">10.7554/eLife.19272</pub-id>
        <pub-id pub-id-type="pmid">28186491</pub-id>
      </element-citation>
    </ref>
    <ref id="B39-ijms-24-01891">
      <label>39.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Misra</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Rapin</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Akhova</surname>
            <given-names>O.</given-names>
          </name>
          <name>
            <surname>Bainbridge</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Korchinski</surname>
            <given-names>P.</given-names>
          </name>
        </person-group>
        <article-title>Zhangfei Is a Potent and Specific Inhibitor of the Host Cell Factor-Binding Transcription Factor Luman</article-title>
        <source>J. Biol. Chem.</source>
        <year>2005</year>
        <volume>280</volume>
        <fpage>15257</fpage>
        <lpage>15266</lpage>
        <pub-id pub-id-type="doi">10.1074/jbc.M500728200</pub-id>
        <pub-id pub-id-type="pmid">15705566</pub-id>
      </element-citation>
    </ref>
    <ref id="B40-ijms-24-01891">
      <label>40.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Peng</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Yuan</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Ling</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Fukasawa</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Robertson</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Olashaw</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Koomen</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Lane</surname>
            <given-names>W.S.</given-names>
          </name>
          <name>
            <surname>Seto</surname>
            <given-names>E.</given-names>
          </name>
        </person-group>
        <article-title>SIRT1 Deacetylates the DNA Methyltransferase 1 (DNMT1) Protein and Alters Its Activities</article-title>
        <source>Mol. Cell. Biol.</source>
        <year>2011</year>
        <volume>31</volume>
        <fpage>4720</fpage>
        <lpage>4734</lpage>
        <pub-id pub-id-type="doi">10.1128/MCB.06147-11</pub-id>
        <pub-id pub-id-type="pmid">21947282</pub-id>
      </element-citation>
    </ref>
    <ref id="B41-ijms-24-01891">
      <label>41.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Iasevoli</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Giordano</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Balletta</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Latte</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Formato</surname>
            <given-names>M.V.</given-names>
          </name>
          <name>
            <surname>Prinzivalli</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>De Berardis</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Tomasetti</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>de Bartolomeis</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>Treatment Resistant Schizophrenia Is Associated with the Worst Community Functioning among Severely-Ill Highly-Disabling Psychiatric Conditions and Is the Most Relevant Predictor of Poorer Achievements in Functional Milestones</article-title>
        <source>Prog. Neuro-Psychopharmacol. Biol. Psychiatr.</source>
        <year>2016</year>
        <volume>65</volume>
        <fpage>34</fpage>
        <lpage>48</lpage>
        <pub-id pub-id-type="doi">10.1016/j.pnpbp.2015.08.010</pub-id>
      </element-citation>
    </ref>
    <ref id="B42-ijms-24-01891">
      <label>42.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Xu</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Tian</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>H.</given-names>
          </name>
        </person-group>
        <article-title>Down-Regulation of ID2-AS1 Alleviates the Neuronal Injury Induced by 1-Methy1-4-Phenylpyridinium in Human Neuroblastoma Cell Line SH-SY5Y Cells Through Regulating MiR-199a-5p/IFNAR1/JAK2/STAT1 Axis</article-title>
        <source>Neurochem. Res.</source>
        <year>2021</year>
        <volume>46</volume>
        <fpage>2192</fpage>
        <lpage>2203</lpage>
        <pub-id pub-id-type="doi">10.1007/s11064-021-03356-4</pub-id>
        <pub-id pub-id-type="pmid">34050453</pub-id>
      </element-citation>
    </ref>
    <ref id="B43-ijms-24-01891">
      <label>43.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Minter</surname>
            <given-names>M.R.</given-names>
          </name>
          <name>
            <surname>Moore</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Brody</surname>
            <given-names>K.M.</given-names>
          </name>
          <name>
            <surname>Jones</surname>
            <given-names>N.C.</given-names>
          </name>
          <name>
            <surname>Shultz</surname>
            <given-names>S.R.</given-names>
          </name>
          <name>
            <surname>Taylor</surname>
            <given-names>J.M.</given-names>
          </name>
          <name>
            <surname>Crack</surname>
            <given-names>P.J.</given-names>
          </name>
        </person-group>
        <article-title>Deletion of the Type-1 Interferon Receptor in APPSWE/PS1ΔE9 Mice Preserves Cognitive Function and Alters Glial Phenotype</article-title>
        <source>Acta Neuropathol. Commun.</source>
        <year>2016</year>
        <volume>4</volume>
        <fpage>72</fpage>
        <pub-id pub-id-type="doi">10.1186/s40478-016-0341-4</pub-id>
        <pub-id pub-id-type="pmid">27400725</pub-id>
      </element-citation>
    </ref>
    <ref id="B44-ijms-24-01891">
      <label>44.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Madar</surname>
            <given-names>I.H.</given-names>
          </name>
          <name>
            <surname>Sultan</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Tayubi</surname>
            <given-names>I.A.</given-names>
          </name>
          <name>
            <surname>Hasan</surname>
            <given-names>A.N.</given-names>
          </name>
          <name>
            <surname>Pahi</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Rai</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Sivanandan</surname>
            <given-names>P.K.</given-names>
          </name>
          <name>
            <surname>Loganathan</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Begum</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Rai</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>Identification of Marker Genes in Alzheimer’s Disease Using a Machine-Learning Model</article-title>
        <source>Bioinformation</source>
        <year>2021</year>
        <volume>17</volume>
        <fpage>348</fpage>
        <lpage>355</lpage>
        <pub-id pub-id-type="doi">10.6026/97320630017363</pub-id>
        <pub-id pub-id-type="pmid">34234395</pub-id>
      </element-citation>
    </ref>
    <ref id="B45-ijms-24-01891">
      <label>45.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tolosa</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Botta-Orfila</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Morató</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Calatayud</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Ferrer-Lorente</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Martí</surname>
            <given-names>M.-J.</given-names>
          </name>
          <name>
            <surname>Fernández</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Gaig</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Raya</surname>
            <given-names>Á.</given-names>
          </name>
          <name>
            <surname>Consiglio</surname>
            <given-names>A.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MicroRNA Alterations in IPSC-Derived Dopaminergic Neurons from Parkinson Disease Patients</article-title>
        <source>Neurobiol. Aging</source>
        <year>2018</year>
        <volume>69</volume>
        <fpage>283</fpage>
        <lpage>291</lpage>
        <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2018.05.032</pub-id>
        <?supplied-pmid 29935433?>
        <pub-id pub-id-type="pmid">29935433</pub-id>
      </element-citation>
    </ref>
    <ref id="B46-ijms-24-01891">
      <label>46.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Qiu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Meng</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Wei</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Mo</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Zou</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>C.</given-names>
          </name>
        </person-group>
        <article-title>A Potential Autophagy-Related Competing Endogenous RNA Network and Corresponding Diagnostic Efficacy in Schizophrenia</article-title>
        <source>Front. Psychiatr.</source>
        <year>2021</year>
        <volume>12</volume>
        <fpage>628361</fpage>
        <pub-id pub-id-type="doi">10.3389/fpsyt.2021.628361</pub-id>
        <?supplied-pmid 33708146?>
        <pub-id pub-id-type="pmid">33708146</pub-id>
      </element-citation>
    </ref>
    <ref id="B47-ijms-24-01891">
      <label>47.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Choi</surname>
            <given-names>S.-Y.</given-names>
          </name>
          <name>
            <surname>Pang</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>J.Y.</given-names>
          </name>
          <name>
            <surname>Ryu</surname>
            <given-names>J.R.</given-names>
          </name>
          <name>
            <surname>Kang</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>W.-K.</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Han</surname>
            <given-names>K.</given-names>
          </name>
        </person-group>
        <article-title>Post-Transcriptional Regulation of SHANK3 Expression by MicroRNAs Related to Multiple Neuropsychiatric Disorders</article-title>
        <source>Mol. Brain</source>
        <year>2015</year>
        <volume>8</volume>
        <fpage>74</fpage>
        <pub-id pub-id-type="doi">10.1186/s13041-015-0165-3</pub-id>
        <?supplied-pmid 26572867?>
        <pub-id pub-id-type="pmid">26572867</pub-id>
      </element-citation>
    </ref>
    <ref id="B48-ijms-24-01891">
      <label>48.</label>
      <element-citation publication-type="webpage">
        <article-title>MalaCards—Human Disease Database</article-title>
        <comment>Available online: <ext-link xlink:href="https://www.malacards.org/" ext-link-type="uri">https://www.malacards.org/</ext-link></comment>
        <date-in-citation content-type="access-date" iso-8601-date="2022-11-10">(accessed on 10 November 2022)</date-in-citation>
      </element-citation>
    </ref>
    <ref id="B49-ijms-24-01891">
      <label>49.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>A.H.</given-names>
          </name>
          <name>
            <surname>Reimers</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Maher</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Williamson</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>McMichael</surname>
            <given-names>O.</given-names>
          </name>
          <name>
            <surname>McClay</surname>
            <given-names>J.L.</given-names>
          </name>
          <name>
            <surname>van den Oord</surname>
            <given-names>E.J.C.G.</given-names>
          </name>
          <name>
            <surname>Riley</surname>
            <given-names>B.P.</given-names>
          </name>
          <name>
            <surname>Kendler</surname>
            <given-names>K.S.</given-names>
          </name>
          <name>
            <surname>Vladimirov</surname>
            <given-names>V.I.</given-names>
          </name>
        </person-group>
        <article-title>MicroRNA Expression Profiling in the Prefrontal Cortex of Individuals Affected with Schizophrenia and Bipolar Disorders</article-title>
        <source>Schizophr. Res.</source>
        <year>2010</year>
        <volume>124</volume>
        <fpage>183</fpage>
        <lpage>191</lpage>
        <pub-id pub-id-type="doi">10.1016/j.schres.2010.07.002</pub-id>
        <?supplied-pmid 20675101?>
        <pub-id pub-id-type="pmid">20675101</pub-id>
      </element-citation>
    </ref>
    <ref id="B50-ijms-24-01891">
      <label>50.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Guo</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Fan</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Du</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Ye</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>L.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A 9-MicroRNA Signature in Serum Serves as a Noninvasive Biomarker in Early Diagnosis of Alzheimer’s Disease</article-title>
        <source>J. Alzheimers Dis.</source>
        <year>2017</year>
        <volume>60</volume>
        <fpage>1365</fpage>
        <lpage>1377</lpage>
        <pub-id pub-id-type="doi">10.3233/JAD-170343</pub-id>
        <pub-id pub-id-type="pmid">29036818</pub-id>
      </element-citation>
    </ref>
    <ref id="B51-ijms-24-01891">
      <label>51.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ignacio</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Hicks</surname>
            <given-names>S.D.</given-names>
          </name>
          <name>
            <surname>Burke</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Lewis</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Szombathyne-Meszaros</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Middleton</surname>
            <given-names>F.A.</given-names>
          </name>
        </person-group>
        <article-title>Alterations in Serum MicroRNA in Humans with Alcohol Use Disorders Impact Cell Proliferation and Cell Death Pathways and Predict Structural and Functional Changes in Brain</article-title>
        <source>BMC Neurosci.</source>
        <year>2015</year>
        <volume>16</volume>
        <elocation-id>55</elocation-id>
        <pub-id pub-id-type="doi">10.1186/s12868-015-0195-x</pub-id>
        <pub-id pub-id-type="pmid">26341662</pub-id>
      </element-citation>
    </ref>
    <ref id="B52-ijms-24-01891">
      <label>52.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pala</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Denkçeken</surname>
            <given-names>T.</given-names>
          </name>
        </person-group>
        <article-title>Evaluation of MiRNA Expression Profiles in Schizophrenia Using Principal-Component Analysis-Based Unsupervised Feature Extraction Method</article-title>
        <source>J. Comput. Biol.</source>
        <year>2020</year>
        <volume>27</volume>
        <fpage>1253</fpage>
        <lpage>1263</lpage>
        <pub-id pub-id-type="doi">10.1089/cmb.2019.0412</pub-id>
        <pub-id pub-id-type="pmid">31855458</pub-id>
      </element-citation>
    </ref>
    <ref id="B53-ijms-24-01891">
      <label>53.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ceylan</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Tufekci</surname>
            <given-names>K.U.</given-names>
          </name>
          <name>
            <surname>Keskinoglu</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Genc</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Özerdem</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>Circulating Exosomal MicroRNAs in Bipolar Disorder</article-title>
        <source>J. Affect. Disord.</source>
        <year>2020</year>
        <volume>262</volume>
        <fpage>99</fpage>
        <lpage>107</lpage>
        <pub-id pub-id-type="doi">10.1016/j.jad.2019.10.038</pub-id>
        <pub-id pub-id-type="pmid">31726266</pub-id>
      </element-citation>
    </ref>
    <ref id="B54-ijms-24-01891">
      <label>54.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lu</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Dai</surname>
            <given-names>W.-Z.</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>X.-C.</given-names>
          </name>
          <name>
            <surname>Ma</surname>
            <given-names>T.</given-names>
          </name>
        </person-group>
        <article-title>Analysis of Serum MiRNAs in Alzheimer’s Disease</article-title>
        <source>Am. J. Alzheimers Dis. Other Demen.</source>
        <year>2021</year>
        <volume>36</volume>
        <fpage>15333175211021712</fpage>
        <pub-id pub-id-type="doi">10.1177/15333175211021712</pub-id>
        <pub-id pub-id-type="pmid">34080437</pub-id>
      </element-citation>
    </ref>
    <ref id="B55-ijms-24-01891">
      <label>55.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sun</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>P.</given-names>
          </name>
        </person-group>
        <article-title>Identification of Gene Signatures and Potential Therapeutic Targets for Acquired Chemotherapy Resistance in Gastric Cancer Patients</article-title>
        <source>J. Gastrointest Oncol.</source>
        <year>2021</year>
        <volume>12</volume>
        <fpage>407</fpage>
        <lpage>422</lpage>
        <pub-id pub-id-type="doi">10.21037/jgo-21-81</pub-id>
        <pub-id pub-id-type="pmid">34012635</pub-id>
      </element-citation>
    </ref>
    <ref id="B56-ijms-24-01891">
      <label>56.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tekin</surname>
            <given-names>S.S.</given-names>
          </name>
          <name>
            <surname>Erdal</surname>
            <given-names>M.E.</given-names>
          </name>
          <name>
            <surname>Asoğlu</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Ay</surname>
            <given-names>Ö.İ.</given-names>
          </name>
          <name>
            <surname>Ay</surname>
            <given-names>M.E.</given-names>
          </name>
          <name>
            <surname>Yılmaz</surname>
            <given-names>Ş.G.</given-names>
          </name>
        </person-group>
        <article-title>Biomarker Potential of Hsa-MiR-145-5p in Peripheral Whole Blood of Manic Bipolar I Patients</article-title>
        <source>Braz. J. Psychiatr.</source>
        <year>2022</year>
        <volume>44</volume>
        <fpage>378</fpage>
        <lpage>387</lpage>
        <pub-id pub-id-type="doi">10.47626/1516-4446-2021-2260</pub-id>
        <?supplied-pmid 35749663?>
        <pub-id pub-id-type="pmid">35749663</pub-id>
      </element-citation>
    </ref>
    <ref id="B57-ijms-24-01891">
      <label>57.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Piatkov</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Caetano</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Assur</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Lau</surname>
            <given-names>S.L.</given-names>
          </name>
          <name>
            <surname>Jones</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Boyages</surname>
            <given-names>S.C.</given-names>
          </name>
          <name>
            <surname>McLean</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>ABCB1 and ABCC1 Single-Nucleotide Polymorphisms in Patients Treated with Clozapine</article-title>
        <source>Pharm. Pers. Med.</source>
        <year>2017</year>
        <volume>10</volume>
        <fpage>235</fpage>
        <lpage>242</lpage>
        <pub-id pub-id-type="doi">10.2147/PGPM.S142314</pub-id>
      </element-citation>
    </ref>
    <ref id="B58-ijms-24-01891">
      <label>58.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sakatis</surname>
            <given-names>M.Z.</given-names>
          </name>
          <name>
            <surname>Reese</surname>
            <given-names>M.J.</given-names>
          </name>
          <name>
            <surname>Harrell</surname>
            <given-names>A.W.</given-names>
          </name>
          <name>
            <surname>Taylor</surname>
            <given-names>M.A.</given-names>
          </name>
          <name>
            <surname>Baines</surname>
            <given-names>I.A.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Bloomer</surname>
            <given-names>J.C.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>E.Y.</given-names>
          </name>
          <name>
            <surname>Ellens</surname>
            <given-names>H.M.</given-names>
          </name>
          <name>
            <surname>Ambroso</surname>
            <given-names>J.L.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Preclinical Strategy to Reduce Clinical Hepatotoxicity Using in Vitro Bioactivation Data for &gt;200 Compounds</article-title>
        <source>Chem. Res. Toxicol.</source>
        <year>2012</year>
        <volume>25</volume>
        <fpage>2067</fpage>
        <lpage>2082</lpage>
        <pub-id pub-id-type="doi">10.1021/tx300075j</pub-id>
        <?supplied-pmid 22931300?>
        <pub-id pub-id-type="pmid">22931300</pub-id>
      </element-citation>
    </ref>
    <ref id="B59-ijms-24-01891">
      <label>59.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Milosavljević</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Bukvić</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Pavlović</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Miljević</surname>
            <given-names>Č.</given-names>
          </name>
          <name>
            <surname>Pešić</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Molden</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Ingelman-Sundberg</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Leucht</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Jukić</surname>
            <given-names>M.M.</given-names>
          </name>
        </person-group>
        <article-title>Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status with Antidepressant and Antipsychotic Exposure</article-title>
        <source>JAMA Psychiatr.</source>
        <year>2021</year>
        <volume>78</volume>
        <fpage>270</fpage>
        <lpage>280</lpage>
        <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2020.3643</pub-id>
      </element-citation>
    </ref>
    <ref id="B60-ijms-24-01891">
      <label>60.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Song</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Yan</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Ju</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Shi</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>Effect of CYP2C19 Polymorphisms on Serum Valproic Level Acid in Chinese Han Patients with Schizophrenia</article-title>
        <source>Sci. Rep.</source>
        <year>2021</year>
        <volume>11</volume>
        <fpage>23150</fpage>
        <pub-id pub-id-type="doi">10.1038/s41598-021-02628-x</pub-id>
        <pub-id pub-id-type="pmid">34848811</pub-id>
      </element-citation>
    </ref>
    <ref id="B61-ijms-24-01891">
      <label>61.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zastrozhin</surname>
            <given-names>M.S.</given-names>
          </name>
          <name>
            <surname>Skryabin</surname>
            <given-names>V.Y.</given-names>
          </name>
          <name>
            <surname>Torrado</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Petrovna</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Sorokin</surname>
            <given-names>A.S.</given-names>
          </name>
          <name>
            <surname>Grishina</surname>
            <given-names>E.A.</given-names>
          </name>
          <name>
            <surname>Ryzhikova</surname>
            <given-names>K.A.</given-names>
          </name>
          <name>
            <surname>Bedina</surname>
            <given-names>I.A.</given-names>
          </name>
          <name>
            <surname>Buzik</surname>
            <given-names>O.Z.</given-names>
          </name>
          <name>
            <surname>Chumakov</surname>
            <given-names>E.M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Effects of CYP2C19*2 Polymorphisms on the Efficacy and Safety of Phenazepam in Patients with Anxiety Disorder and Comorbid Alcohol Use Disorder</article-title>
        <source>Pharmacogenomics</source>
        <year>2020</year>
        <volume>21</volume>
        <fpage>111</fpage>
        <lpage>123</lpage>
        <pub-id pub-id-type="doi">10.2217/pgs-2019-0019</pub-id>
        <pub-id pub-id-type="pmid">31957548</pub-id>
      </element-citation>
    </ref>
    <ref id="B62-ijms-24-01891">
      <label>62.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kanehisa</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Goto</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>KEGG: Kyoto Encyclopedia of Genes and Genomes</article-title>
        <source>Nucl. Acids Res.</source>
        <year>2000</year>
        <volume>28</volume>
        <fpage>27</fpage>
        <lpage>30</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/28.1.27</pub-id>
        <?supplied-pmid 10592173?>
        <pub-id pub-id-type="pmid">10592173</pub-id>
      </element-citation>
    </ref>
    <ref id="B63-ijms-24-01891">
      <label>63.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pirmohamed</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Williams</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Madden</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Templeton</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Park</surname>
            <given-names>B.K.</given-names>
          </name>
        </person-group>
        <article-title>Metabolism and Bioactivation of Clozapine by Human Liver in Vitro</article-title>
        <source>J. Pharmacol. Exp. Ther.</source>
        <year>1995</year>
        <volume>272</volume>
        <fpage>984</fpage>
        <lpage>990</lpage>
        <pub-id pub-id-type="pmid">7891353</pub-id>
      </element-citation>
    </ref>
    <ref id="B64-ijms-24-01891">
      <label>64.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Haddad</surname>
            <given-names>P.M.</given-names>
          </name>
          <name>
            <surname>Brain</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Scott</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>Nonadherence with Antipsychotic Medication in Schizophrenia: Challenges and Management Strategies</article-title>
        <source>Patient Relat. Outcome Meas.</source>
        <year>2014</year>
        <volume>5</volume>
        <fpage>43</fpage>
        <lpage>62</lpage>
        <pub-id pub-id-type="doi">10.2147/PROM.S42735</pub-id>
        <pub-id pub-id-type="pmid">25061342</pub-id>
      </element-citation>
    </ref>
    <ref id="B65-ijms-24-01891">
      <label>65.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Valenstein</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Blow</surname>
            <given-names>F.C.</given-names>
          </name>
          <name>
            <surname>Copeland</surname>
            <given-names>L.A.</given-names>
          </name>
          <name>
            <surname>McCarthy</surname>
            <given-names>J.F.</given-names>
          </name>
          <name>
            <surname>Zeber</surname>
            <given-names>J.E.</given-names>
          </name>
          <name>
            <surname>Gillon</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Bingham</surname>
            <given-names>C.R.</given-names>
          </name>
          <name>
            <surname>Stavenger</surname>
            <given-names>T.</given-names>
          </name>
        </person-group>
        <article-title>Poor Antipsychotic Adherence Among Patients With Schizophrenia: Medication and Patient Factors</article-title>
        <source>Schizophr. Bull.</source>
        <year>2004</year>
        <volume>30</volume>
        <fpage>255</fpage>
        <lpage>264</lpage>
        <pub-id pub-id-type="doi">10.1093/oxfordjournals.schbul.a007076</pub-id>
        <pub-id pub-id-type="pmid">15279044</pub-id>
      </element-citation>
    </ref>
    <ref id="B66-ijms-24-01891">
      <label>66.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lukoff</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Snyder</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Ventura</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Nuechterlein</surname>
            <given-names>K.H.</given-names>
          </name>
        </person-group>
        <article-title>Life Events, Familial Stress, and Coping in the Developmental Course of Schizophrenia</article-title>
        <source>Schizophr. Bull.</source>
        <year>1984</year>
        <volume>10</volume>
        <fpage>258</fpage>
        <lpage>292</lpage>
        <pub-id pub-id-type="doi">10.1093/schbul/10.2.258</pub-id>
        <?supplied-pmid 6729412?>
        <pub-id pub-id-type="pmid">6729412</pub-id>
      </element-citation>
    </ref>
    <ref id="B67-ijms-24-01891">
      <label>67.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Nuechterlein</surname>
            <given-names>K.H.</given-names>
          </name>
          <name>
            <surname>Dawson</surname>
            <given-names>M.E.</given-names>
          </name>
        </person-group>
        <article-title>A Heuristic Vulnerability/Stress Model of Schizophrenic Episodes</article-title>
        <source>Schizophr. Bull.</source>
        <year>1984</year>
        <volume>10</volume>
        <fpage>300</fpage>
        <lpage>312</lpage>
        <pub-id pub-id-type="doi">10.1093/schbul/10.2.300</pub-id>
        <?supplied-pmid 6729414?>
        <pub-id pub-id-type="pmid">6729414</pub-id>
      </element-citation>
    </ref>
    <ref id="B68-ijms-24-01891">
      <label>68.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cheng</surname>
            <given-names>S.C.</given-names>
          </name>
          <name>
            <surname>Walsh</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Schepp</surname>
            <given-names>K.G.</given-names>
          </name>
        </person-group>
        <article-title>Vulnerability, Stress, and Support in the Disease Trajectory from Prodrome to Diagnosed Schizophrenia: Diathesis–Stress–Support Model</article-title>
        <source>Arch. Psychiatr. Nurs.</source>
        <year>2016</year>
        <volume>30</volume>
        <fpage>810</fpage>
        <lpage>817</lpage>
        <pub-id pub-id-type="doi">10.1016/j.apnu.2016.07.008</pub-id>
        <?supplied-pmid 27888978?>
        <pub-id pub-id-type="pmid">27888978</pub-id>
      </element-citation>
    </ref>
    <ref id="B69-ijms-24-01891">
      <label>69.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Walder</surname>
            <given-names>D.J.</given-names>
          </name>
          <name>
            <surname>Faraone</surname>
            <given-names>S.V.</given-names>
          </name>
          <name>
            <surname>Glatt</surname>
            <given-names>S.J.</given-names>
          </name>
          <name>
            <surname>Tsuang</surname>
            <given-names>M.T.</given-names>
          </name>
          <name>
            <surname>Seidman</surname>
            <given-names>L.J.</given-names>
          </name>
        </person-group>
        <article-title>Genetic Liability, Prenatal Health, Stress and Family Environment: Risk Factors in the Harvard Adolescent Family High Risk for Schizophrenia Study</article-title>
        <source>Schizophr. Res.</source>
        <year>2014</year>
        <volume>157</volume>
        <fpage>142</fpage>
        <lpage>148</lpage>
        <pub-id pub-id-type="doi">10.1016/j.schres.2014.04.015</pub-id>
        <?supplied-pmid 24836971?>
        <pub-id pub-id-type="pmid">24836971</pub-id>
      </element-citation>
    </ref>
    <ref id="B70-ijms-24-01891">
      <label>70.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hahlweg</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Baucom</surname>
            <given-names>D.H.</given-names>
          </name>
        </person-group>
        <article-title>Family Therapy for Persons with Schizophrenia: Neglected yet Important</article-title>
        <source>Eur. Arch. Psychiatr. Clin. Neurosci.</source>
        <year>2022</year>
        <pub-id pub-id-type="doi">10.1007/s00406-022-01393-w</pub-id>
      </element-citation>
    </ref>
    <ref id="B71-ijms-24-01891">
      <label>71.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Müller</surname>
            <given-names>N.</given-names>
          </name>
        </person-group>
        <article-title>Inflammation in Schizophrenia: Pathogenetic Aspects and Therapeutic Considerations</article-title>
        <source>Schizophr. Bull.</source>
        <year>2018</year>
        <volume>44</volume>
        <fpage>973</fpage>
        <lpage>982</lpage>
        <pub-id pub-id-type="doi">10.1093/schbul/sby024</pub-id>
        <pub-id pub-id-type="pmid">29648618</pub-id>
      </element-citation>
    </ref>
    <ref id="B72-ijms-24-01891">
      <label>72.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Black</surname>
            <given-names>P.H.</given-names>
          </name>
        </person-group>
        <article-title>Stress and the Inflammatory Response: A Review of Neurogenic Inflammation</article-title>
        <source>Brain Behav. Immun.</source>
        <year>2002</year>
        <volume>16</volume>
        <fpage>622</fpage>
        <lpage>653</lpage>
        <pub-id pub-id-type="doi">10.1016/S0889-1591(02)00021-1</pub-id>
        <pub-id pub-id-type="pmid">12480495</pub-id>
      </element-citation>
    </ref>
    <ref id="B73-ijms-24-01891">
      <label>73.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rodrigues-Amorim</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Rivera-Baltanás</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Spuch</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Caruncho</surname>
            <given-names>H.J.</given-names>
          </name>
          <name>
            <surname>González-Fernandez</surname>
            <given-names>Á.</given-names>
          </name>
          <name>
            <surname>Olivares</surname>
            <given-names>J.M.</given-names>
          </name>
          <name>
            <surname>Agís-Balboa</surname>
            <given-names>R.C.</given-names>
          </name>
        </person-group>
        <article-title>Cytokines Dysregulation in Schizophrenia: A Systematic Review of Psychoneuroimmune Relationship</article-title>
        <source>Schizophr. Res.</source>
        <year>2018</year>
        <volume>197</volume>
        <fpage>19</fpage>
        <lpage>33</lpage>
        <pub-id pub-id-type="doi">10.1016/j.schres.2017.11.023</pub-id>
        <pub-id pub-id-type="pmid">29239785</pub-id>
      </element-citation>
    </ref>
    <ref id="B74-ijms-24-01891">
      <label>74.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rodrigues-Amorim</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Rivera-Baltanás</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Bessa</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Sousa</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>de Carmen Vallejo-Curto</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Rodríguez-Jamardo</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>de Las Heras</surname>
            <given-names>M.E.</given-names>
          </name>
          <name>
            <surname>Díaz</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Agís-Balboa</surname>
            <given-names>R.C.</given-names>
          </name>
          <name>
            <surname>Olivares</surname>
            <given-names>J.M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The Neurobiological Hypothesis of Neurotrophins in the Pathophysiology of Schizophrenia: A Meta-Analysis</article-title>
        <source>J. Psychiatr. Res.</source>
        <year>2018</year>
        <volume>106</volume>
        <fpage>43</fpage>
        <lpage>53</lpage>
        <pub-id pub-id-type="doi">10.1016/j.jpsychires.2018.09.007</pub-id>
        <pub-id pub-id-type="pmid">30269004</pub-id>
      </element-citation>
    </ref>
    <ref id="B75-ijms-24-01891">
      <label>75.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Labonté</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Zhand</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Park</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Harvey</surname>
            <given-names>P.D.</given-names>
          </name>
        </person-group>
        <article-title>Complete Blood Count Inflammatory Markers in Treatment-Resistant Schizophrenia: Evidence of Association between Treatment Responsiveness and Levels of Inflammation</article-title>
        <source>Psychiatr. Res.</source>
        <year>2022</year>
        <volume>308</volume>
        <fpage>114382</fpage>
        <pub-id pub-id-type="doi">10.1016/j.psychres.2021.114382</pub-id>
      </element-citation>
    </ref>
    <ref id="B76-ijms-24-01891">
      <label>76.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lin</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Kenis</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Bignotti</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Tura</surname>
            <given-names>G.-J.-B.</given-names>
          </name>
          <name>
            <surname>De Jong</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Bosmans</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Pioli</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Altamura</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Scharpé</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Maes</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>The Inflammatory Response System in Treatment-Resistant Schizophrenia: Increased Serum Interleukin-6</article-title>
        <source>Schizophr. Res.</source>
        <year>1998</year>
        <volume>32</volume>
        <fpage>9</fpage>
        <lpage>15</lpage>
        <pub-id pub-id-type="doi">10.1016/S0920-9964(98)00034-6</pub-id>
        <?supplied-pmid 9690329?>
        <pub-id pub-id-type="pmid">9690329</pub-id>
      </element-citation>
    </ref>
    <ref id="B77-ijms-24-01891">
      <label>77.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Leboyer</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Godin</surname>
            <given-names>O.</given-names>
          </name>
          <name>
            <surname>Terro</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Boukouaci</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Andre</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Aouizerate</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Berna</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Barau</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Capdevielle</surname>
            <given-names>D.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Immune Signatures of Treatment-Resistant Schizophrenia: A FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) Study</article-title>
        <source>Schizophr. Bull. Open</source>
        <year>2021</year>
        <volume>2</volume>
        <fpage>sgab012</fpage>
        <pub-id pub-id-type="doi">10.1093/schizbullopen/sgab012</pub-id>
        <?supplied-pmid 34901861?>
        <pub-id pub-id-type="pmid">34901861</pub-id>
      </element-citation>
    </ref>
    <ref id="B78-ijms-24-01891">
      <label>78.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Penedo</surname>
            <given-names>M.A.</given-names>
          </name>
          <name>
            <surname>Rivera-Baltanas</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Perez-Rodriguez</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Allen</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Borrajom</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Alonso-Crespo</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Fernández-Pereira</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Nieto-Araujo</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Ramos-García</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Barreiro-Villar</surname>
            <given-names>C.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The Role of Dopamine Receptors in Lymphocytes and Their Changes in Schizophrenia</article-title>
        <source>Brain Behav. Immun.–Health</source>
        <year>2021</year>
        <volume>12</volume>
        <fpage>100199</fpage>
        <pub-id pub-id-type="doi">10.1016/j.bbih.2021.100199</pub-id>
        <?supplied-pmid 34589732?>
        <pub-id pub-id-type="pmid">34589732</pub-id>
      </element-citation>
    </ref>
    <ref id="B79-ijms-24-01891">
      <label>79.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bose</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Ghosh</surname>
            <given-names>B.</given-names>
          </name>
        </person-group>
        <article-title>The P53-MDM2 Network: From Oscillations to Apoptosis</article-title>
        <source>J. Biosci.</source>
        <year>2007</year>
        <volume>32</volume>
        <fpage>991</fpage>
        <lpage>997</lpage>
        <pub-id pub-id-type="doi">10.1007/s12038-007-0103-3</pub-id>
        <?supplied-pmid 17914240?>
        <pub-id pub-id-type="pmid">17914240</pub-id>
      </element-citation>
    </ref>
    <ref id="B80-ijms-24-01891">
      <label>80.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tong</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Xiao</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>YB-1 Modulates the Drug Resistance of Glioma Cells by Activation of MDM2/P53 Pathway</article-title>
        <source>Drug Des. Devel.</source>
        <year>2019</year>
        <volume>13</volume>
        <fpage>317</fpage>
        <lpage>326</lpage>
        <pub-id pub-id-type="doi">10.2147/DDDT.S185514</pub-id>
        <?supplied-pmid 30679904?>
        <pub-id pub-id-type="pmid">30679904</pub-id>
      </element-citation>
    </ref>
    <ref id="B81-ijms-24-01891">
      <label>81.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hou</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>X.</given-names>
          </name>
        </person-group>
        <article-title>The Role of MDM2 Amplification and Overexpression in Therapeutic Resistance of Malignant Tumors</article-title>
        <source>Cancer Cell Int.</source>
        <year>2019</year>
        <volume>19</volume>
        <fpage>216</fpage>
        <pub-id pub-id-type="doi">10.1186/s12935-019-0937-4</pub-id>
        <?supplied-pmid 31440117?>
        <pub-id pub-id-type="pmid">31440117</pub-id>
      </element-citation>
    </ref>
    <ref id="B82-ijms-24-01891">
      <label>82.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tweddle</surname>
            <given-names>D.A.</given-names>
          </name>
          <name>
            <surname>Pearson</surname>
            <given-names>A.D.J.</given-names>
          </name>
          <name>
            <surname>Haber</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Norris</surname>
            <given-names>M.D.</given-names>
          </name>
          <name>
            <surname>Xue</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Flemming</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Lunec</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>The P53 Pathway and Its Inactivation in Neuroblastoma</article-title>
        <source>Cancer Lett.</source>
        <year>2003</year>
        <volume>197</volume>
        <fpage>93</fpage>
        <lpage>98</lpage>
        <pub-id pub-id-type="doi">10.1016/S0304-3835(03)00088-0</pub-id>
        <pub-id pub-id-type="pmid">12880966</pub-id>
      </element-citation>
    </ref>
    <ref id="B83-ijms-24-01891">
      <label>83.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zafar</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Xian</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>McKeon</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>R.</given-names>
          </name>
        </person-group>
        <article-title>Targeting the P53-MDM2 Pathway for Neuroblastoma Therapy: Rays of Hope</article-title>
        <source>Cancer Lett.</source>
        <year>2021</year>
        <volume>496</volume>
        <fpage>16</fpage>
        <lpage>29</lpage>
        <pub-id pub-id-type="doi">10.1016/j.canlet.2020.09.023</pub-id>
        <pub-id pub-id-type="pmid">33007410</pub-id>
      </element-citation>
    </ref>
    <ref id="B84-ijms-24-01891">
      <label>84.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Patil</surname>
            <given-names>S.P.</given-names>
          </name>
          <name>
            <surname>Pacitti</surname>
            <given-names>M.F.</given-names>
          </name>
          <name>
            <surname>Gilroy</surname>
            <given-names>K.S.</given-names>
          </name>
          <name>
            <surname>Ruggiero</surname>
            <given-names>J.C.</given-names>
          </name>
          <name>
            <surname>Griffin</surname>
            <given-names>J.D.</given-names>
          </name>
          <name>
            <surname>Butera</surname>
            <given-names>J.J.</given-names>
          </name>
          <name>
            <surname>Notarfrancesco</surname>
            <given-names>J.M.</given-names>
          </name>
          <name>
            <surname>Tran</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Stoddart</surname>
            <given-names>J.W.</given-names>
          </name>
        </person-group>
        <article-title>Identification of Antipsychotic Drug Fluspirilene as a Potential P53-MDM2 Inhibitor: A Combined Computational and Experimental Study</article-title>
        <source>J. Comput. Aided Mol. Des.</source>
        <year>2015</year>
        <volume>29</volume>
        <fpage>155</fpage>
        <lpage>163</lpage>
        <pub-id pub-id-type="doi">10.1007/s10822-014-9811-6</pub-id>
        <pub-id pub-id-type="pmid">25377899</pub-id>
      </element-citation>
    </ref>
    <ref id="B85-ijms-24-01891">
      <label>85.</label>
      <element-citation publication-type="webpage">
        <article-title>Annual Report of the Commissioners in Lunacy to the Lord Chancellor</article-title>
        <comment>Available online: <ext-link xlink:href="https://wellcomecollection.org/works/sgjdfxwv/items" ext-link-type="uri">https://wellcomecollection.org/works/sgjdfxwv/items</ext-link></comment>
        <date-in-citation content-type="access-date" iso-8601-date="2022-11-10">(accessed on 10 November 2022)</date-in-citation>
      </element-citation>
    </ref>
    <ref id="B86-ijms-24-01891">
      <label>86.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mortensen</surname>
            <given-names>P.B.</given-names>
          </name>
        </person-group>
        <article-title>Neuroleptic Treatment and Other Factors Modifying Cancer Risk in Schizophrenic Patients</article-title>
        <source>Acta Psychiatr. Scand.</source>
        <year>1987</year>
        <volume>75</volume>
        <fpage>585</fpage>
        <lpage>590</lpage>
        <pub-id pub-id-type="doi">10.1111/j.1600-0447.1987.tb02839.x</pub-id>
        <pub-id pub-id-type="pmid">2887088</pub-id>
      </element-citation>
    </ref>
    <ref id="B87-ijms-24-01891">
      <label>87.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dalton</surname>
            <given-names>S.O.</given-names>
          </name>
          <name>
            <surname>Johansen</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Poulsen</surname>
            <given-names>A.H.</given-names>
          </name>
          <name>
            <surname>Nørgaard</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Sørensen</surname>
            <given-names>H.T.</given-names>
          </name>
          <name>
            <surname>McLaughlin</surname>
            <given-names>J.K.</given-names>
          </name>
          <name>
            <surname>Mortensen</surname>
            <given-names>P.B.</given-names>
          </name>
          <name>
            <surname>Friis</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>Cancer Risk among Users of Neuroleptic Medication: A Population-Based Cohort Study</article-title>
        <source>Br. J. Cancer</source>
        <year>2006</year>
        <volume>95</volume>
        <fpage>934</fpage>
        <lpage>939</lpage>
        <pub-id pub-id-type="doi">10.1038/sj.bjc.6603259</pub-id>
        <?supplied-pmid 16926836?>
        <pub-id pub-id-type="pmid">16926836</pub-id>
      </element-citation>
    </ref>
    <ref id="B88-ijms-24-01891">
      <label>88.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Grinshpoon</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Barchana</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Ponizovsky</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Lipshitz</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Nahon</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Tal</surname>
            <given-names>O.</given-names>
          </name>
          <name>
            <surname>Weizman</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Levav</surname>
            <given-names>I.</given-names>
          </name>
        </person-group>
        <article-title>Cancer in Schizophrenia: Is the Risk Higher or Lower?</article-title>
        <source>Schizophr. Res.</source>
        <year>2005</year>
        <volume>73</volume>
        <fpage>333</fpage>
        <lpage>341</lpage>
        <pub-id pub-id-type="doi">10.1016/j.schres.2004.06.016</pub-id>
        <?supplied-pmid 15653279?>
        <pub-id pub-id-type="pmid">15653279</pub-id>
      </element-citation>
    </ref>
    <ref id="B89-ijms-24-01891">
      <label>89.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>McGinty</surname>
            <given-names>E.E.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Guallar</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Ford</surname>
            <given-names>D.E.</given-names>
          </name>
          <name>
            <surname>Steinwachs</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Dixon</surname>
            <given-names>L.B.</given-names>
          </name>
          <name>
            <surname>Keating</surname>
            <given-names>N.L.</given-names>
          </name>
          <name>
            <surname>Daumit</surname>
            <given-names>G.L.</given-names>
          </name>
        </person-group>
        <article-title>Cancer Incidence in a Sample of Maryland Residents With Serious Mental Illness</article-title>
        <source>Psychiatr. Serv.</source>
        <year>2012</year>
        <volume>63</volume>
        <fpage>714</fpage>
        <lpage>717</lpage>
        <pub-id pub-id-type="doi">10.1176/appi.ps.201100169</pub-id>
        <?supplied-pmid 22752037?>
        <pub-id pub-id-type="pmid">22752037</pub-id>
      </element-citation>
    </ref>
    <ref id="B90-ijms-24-01891">
      <label>90.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gao</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Mi</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Guo</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Jiang</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Gou</surname>
            <given-names>X.</given-names>
          </name>
        </person-group>
        <article-title>Glioma in Schizophrenia: Is the Risk Higher or Lower?</article-title>
        <source>Front. Cell. Neurosci.</source>
        <year>2018</year>
        <volume>12</volume>
        <fpage>289</fpage>
        <pub-id pub-id-type="doi">10.3389/fncel.2018.00289</pub-id>
        <pub-id pub-id-type="pmid">30233327</pub-id>
      </element-citation>
    </ref>
    <ref id="B91-ijms-24-01891">
      <label>91.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ge</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Huo</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Du</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Wen</surname>
            <given-names>Y.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Association between Schizophrenia and Prostate Cancer Risk: Results from a Pool of Cohort Studies and Mendelian Randomization Analysis</article-title>
        <source>Compr. Psychiatr.</source>
        <year>2022</year>
        <volume>115</volume>
        <fpage>152308</fpage>
        <pub-id pub-id-type="doi">10.1016/j.comppsych.2022.152308</pub-id>
        <?supplied-pmid 35303584?>
        <pub-id pub-id-type="pmid">35303584</pub-id>
      </element-citation>
    </ref>
    <ref id="B92-ijms-24-01891">
      <label>92.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cui</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Gu</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Gu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Yin</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Fang</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>L.</given-names>
          </name>
        </person-group>
        <article-title>Alteration in the MRNA Expression Profile of the Autophagy-Related MTOR Pathway in Schizophrenia Patients Treated with Olanzapine</article-title>
        <source>BMC Psychiatr.</source>
        <year>2021</year>
        <volume>21</volume>
        <elocation-id>388</elocation-id>
        <pub-id pub-id-type="doi">10.1186/s12888-021-03394-w</pub-id>
        <?supplied-pmid 34348681?>
        <pub-id pub-id-type="pmid">34348681</pub-id>
      </element-citation>
    </ref>
    <ref id="B93-ijms-24-01891">
      <label>93.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Vucicevic</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Misirkic-Marjanovic</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Paunovic</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Kravic-Stevovic</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Martinovic</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Ciric</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Maric</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Petricevic</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Harhaji-Trajkovic</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Bumbasirevic</surname>
            <given-names>V.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Autophagy Inhibition Uncovers the Neurotoxic Action of the Antipsychotic Drug Olanzapine</article-title>
        <source>Autophagy</source>
        <year>2014</year>
        <volume>10</volume>
        <fpage>2362</fpage>
        <lpage>2378</lpage>
        <pub-id pub-id-type="doi">10.4161/15548627.2014.984270</pub-id>
        <?supplied-pmid 25551567?>
        <pub-id pub-id-type="pmid">25551567</pub-id>
      </element-citation>
    </ref>
    <ref id="B94-ijms-24-01891">
      <label>94.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhuo</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Hou</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Dou</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Ma</surname>
            <given-names>X.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Mechanistic/Mammalian Target of Rapamycin and Side Effects of Antipsychotics: Insights into Mechanisms and Implications for Therapy</article-title>
        <source>Transl. Psychiatr.</source>
        <year>2022</year>
        <volume>12</volume>
        <fpage>13</fpage>
        <pub-id pub-id-type="doi">10.1038/s41398-021-01778-w</pub-id>
        <?supplied-pmid 35013125?>
        <pub-id pub-id-type="pmid">35013125</pub-id>
      </element-citation>
    </ref>
    <ref id="B95-ijms-24-01891">
      <label>95.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lacroix</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Riscal</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Arena</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Linares</surname>
            <given-names>L.K.</given-names>
          </name>
          <name>
            <surname>Le Cam</surname>
            <given-names>L.</given-names>
          </name>
        </person-group>
        <article-title>Metabolic Functions of the Tumor Suppressor P53: Implications in Normal Physiology, Metabolic Disorders, and Cancer</article-title>
        <source>Mol. Metab.</source>
        <year>2020</year>
        <volume>33</volume>
        <fpage>2</fpage>
        <lpage>22</lpage>
        <pub-id pub-id-type="doi">10.1016/j.molmet.2019.10.002</pub-id>
        <pub-id pub-id-type="pmid">31685430</pub-id>
      </element-citation>
    </ref>
    <ref id="B96-ijms-24-01891">
      <label>96.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Andrews</surname>
            <given-names>J.L.</given-names>
          </name>
          <name>
            <surname>Goodfellow</surname>
            <given-names>F.J.</given-names>
          </name>
          <name>
            <surname>Matosin</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Snelling</surname>
            <given-names>M.K.</given-names>
          </name>
          <name>
            <surname>Newell</surname>
            <given-names>K.A.</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>X.-F.</given-names>
          </name>
          <name>
            <surname>Fernandez-Enright</surname>
            <given-names>F.</given-names>
          </name>
        </person-group>
        <article-title>Alterations of Ubiquitin Related Proteins in the Pathology and Development of Schizophrenia: Evidence from Human and Animal Studies</article-title>
        <source>J. Psychiatr. Res.</source>
        <year>2017</year>
        <volume>90</volume>
        <fpage>31</fpage>
        <lpage>39</lpage>
        <pub-id pub-id-type="doi">10.1016/j.jpsychires.2017.01.009</pub-id>
        <pub-id pub-id-type="pmid">28226265</pub-id>
      </element-citation>
    </ref>
    <ref id="B97-ijms-24-01891">
      <label>97.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Maqsood</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Sumrin</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Mahnoor</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Waseem</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Tabassum</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Bhattacharya</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Saraf</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Bose</surname>
            <given-names>D.</given-names>
          </name>
        </person-group>
        <article-title>Tumor Suppressor Protein P53 and Association of Its Gene TP53 with Schizophrenia Patients</article-title>
        <source>Gene Rep.</source>
        <year>2021</year>
        <volume>25</volume>
        <fpage>101402</fpage>
        <pub-id pub-id-type="doi">10.1016/j.genrep.2021.101402</pub-id>
      </element-citation>
    </ref>
    <ref id="B98-ijms-24-01891">
      <label>98.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ni</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Trakalo</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Valente</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Azevedo</surname>
            <given-names>M.H.</given-names>
          </name>
          <name>
            <surname>Pato</surname>
            <given-names>M.T.</given-names>
          </name>
          <name>
            <surname>Pato</surname>
            <given-names>C.N.</given-names>
          </name>
          <name>
            <surname>Kennedy</surname>
            <given-names>J.L.</given-names>
          </name>
        </person-group>
        <article-title>Human P53 Tumor Suppressor Gene (TP53) and Schizophrenia: Case–Control and Family Studies</article-title>
        <source>Neurosci. Lett.</source>
        <year>2005</year>
        <volume>388</volume>
        <fpage>173</fpage>
        <lpage>178</lpage>
        <pub-id pub-id-type="doi">10.1016/j.neulet.2005.06.050</pub-id>
        <?supplied-pmid 16039051?>
        <pub-id pub-id-type="pmid">16039051</pub-id>
      </element-citation>
    </ref>
    <ref id="B99-ijms-24-01891">
      <label>99.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hiramoto</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Yamate</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Sato</surname>
            <given-names>E.F.</given-names>
          </name>
        </person-group>
        <article-title>P53 and Clock Genes Play an Important Role in Memory and Learning Ability Depression Due to Long-Term Ultraviolet A Eye Irradiation</article-title>
        <source>Photochem. Photobiol. Sci.</source>
        <year>2021</year>
        <volume>20</volume>
        <fpage>677</fpage>
        <lpage>685</lpage>
        <pub-id pub-id-type="doi">10.1007/s43630-021-00055-5</pub-id>
        <?supplied-pmid 34009633?>
        <pub-id pub-id-type="pmid">34009633</pub-id>
      </element-citation>
    </ref>
    <ref id="B100-ijms-24-01891">
      <label>100.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rasheed</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Asghar</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Firdoos</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Ahmad</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Nazir</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Ullah</surname>
            <given-names>K.M.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Zhuang</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Deng</surname>
            <given-names>Y.</given-names>
          </name>
        </person-group>
        <article-title>A Systematic Review of Circulatory MicroRNAs in Major Depressive Disorder: Potential Biomarkers for Disease Prognosis</article-title>
        <source>Int. J. Mol. Sci.</source>
        <year>2022</year>
        <volume>23</volume>
        <elocation-id>1294</elocation-id>
        <pub-id pub-id-type="doi">10.3390/ijms23031294</pub-id>
        <?supplied-pmid 35163214?>
        <pub-id pub-id-type="pmid">35163214</pub-id>
      </element-citation>
    </ref>
    <ref id="B101-ijms-24-01891">
      <label>101.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>Y.-C.</given-names>
          </name>
          <name>
            <surname>Young</surname>
            <given-names>M.-J.</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>H.-P.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>C.-Y.</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>C.-C.</given-names>
          </name>
          <name>
            <surname>Tseng</surname>
            <given-names>Y.-L.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y.-C.</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>W.-C.</given-names>
          </name>
          <name>
            <surname>Hung</surname>
            <given-names>J.-J.</given-names>
          </name>
        </person-group>
        <article-title>Estradiol-Mediated Inhibition of DNMT1 Decreases P53 Expression to Induce M2-Macrophage Polarization in Lung Cancer Progression</article-title>
        <source>Oncogenesis</source>
        <year>2022</year>
        <volume>11</volume>
        <fpage>25</fpage>
        <pub-id pub-id-type="doi">10.1038/s41389-022-00397-4</pub-id>
        <?supplied-pmid 35589688?>
        <pub-id pub-id-type="pmid">35589688</pub-id>
      </element-citation>
    </ref>
    <ref id="B102-ijms-24-01891">
      <label>102.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Du</surname>
            <given-names>W.W.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Awan</surname>
            <given-names>F.M.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Fang</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Lyu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Peng</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Krylov</surname>
            <given-names>S.N.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A Circular RNA Circ-DNMT1 Enhances Breast Cancer Progression by Activating Autophagy</article-title>
        <source>Oncogene</source>
        <year>2018</year>
        <volume>37</volume>
        <fpage>5829</fpage>
        <lpage>5842</lpage>
        <pub-id pub-id-type="doi">10.1038/s41388-018-0369-y</pub-id>
        <pub-id pub-id-type="pmid">29973691</pub-id>
      </element-citation>
    </ref>
    <ref id="B103-ijms-24-01891">
      <label>103.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Bian</surname>
            <given-names>E.-B.</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>X.-J.</given-names>
          </name>
          <name>
            <surname>Ma</surname>
            <given-names>C.-C.</given-names>
          </name>
          <name>
            <surname>Zong</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>H.-L.</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>B.</given-names>
          </name>
        </person-group>
        <article-title>Epigenetic Repression of Long Non-Coding RNA MEG3 Mediated by DNMT1 Represses the P53 Pathway in Gliomas</article-title>
        <source>Int. J. Oncol.</source>
        <year>2016</year>
        <volume>48</volume>
        <fpage>723</fpage>
        <lpage>733</lpage>
        <pub-id pub-id-type="doi">10.3892/ijo.2015.3285</pub-id>
        <?supplied-pmid 26676363?>
        <pub-id pub-id-type="pmid">26676363</pub-id>
      </element-citation>
    </ref>
    <ref id="B104-ijms-24-01891">
      <label>104.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Langley</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Pearson</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Faretta</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Bauer</surname>
            <given-names>U.-M.</given-names>
          </name>
          <name>
            <surname>Frye</surname>
            <given-names>R.A.</given-names>
          </name>
          <name>
            <surname>Minucci</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Pelicci</surname>
            <given-names>P.G.</given-names>
          </name>
          <name>
            <surname>Kouzarides</surname>
            <given-names>T.</given-names>
          </name>
        </person-group>
        <article-title>Human SIR2 Deacetylates P53 and Antagonizes PML/P53-Induced Cellular Senescence</article-title>
        <source>EMBO J.</source>
        <year>2002</year>
        <volume>21</volume>
        <fpage>2383</fpage>
        <lpage>2396</lpage>
        <pub-id pub-id-type="doi">10.1093/emboj/21.10.2383</pub-id>
        <?supplied-pmid 12006491?>
        <pub-id pub-id-type="pmid">12006491</pub-id>
      </element-citation>
    </ref>
    <ref id="B105-ijms-24-01891">
      <label>105.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>J.T.</given-names>
          </name>
          <name>
            <surname>Gu</surname>
            <given-names>W.</given-names>
          </name>
        </person-group>
        <article-title>SIRT1: Regulator of P53 Deacetylation</article-title>
        <source>Genes Cancer</source>
        <year>2013</year>
        <volume>4</volume>
        <fpage>112</fpage>
        <lpage>117</lpage>
        <pub-id pub-id-type="doi">10.1177/1947601913484496</pub-id>
        <pub-id pub-id-type="pmid">24020002</pub-id>
      </element-citation>
    </ref>
    <ref id="B106-ijms-24-01891">
      <label>106.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Vaziri</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Dessain</surname>
            <given-names>S.K.</given-names>
          </name>
          <name>
            <surname>Eaton</surname>
            <given-names>E.N.</given-names>
          </name>
          <name>
            <surname>Imai</surname>
            <given-names>S.-I.</given-names>
          </name>
          <name>
            <surname>Frye</surname>
            <given-names>R.A.</given-names>
          </name>
          <name>
            <surname>Pandita</surname>
            <given-names>T.K.</given-names>
          </name>
          <name>
            <surname>Guarente</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Weinberg</surname>
            <given-names>R.A.</given-names>
          </name>
        </person-group>
        <article-title>HSIR2SIRT1 Functions as an NAD-Dependent P53 Deacetylase</article-title>
        <source>Cell</source>
        <year>2001</year>
        <volume>107</volume>
        <fpage>149</fpage>
        <lpage>159</lpage>
        <pub-id pub-id-type="doi">10.1016/S0092-8674(01)00527-X</pub-id>
        <pub-id pub-id-type="pmid">11672523</pub-id>
      </element-citation>
    </ref>
    <ref id="B107-ijms-24-01891">
      <label>107.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sammad</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Luo</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y.</given-names>
          </name>
        </person-group>
        <article-title>Transcriptome Reveals Granulosa Cells Coping through Redox, Inflammatory and Metabolic Mechanisms under Acute Heat Stress</article-title>
        <source>Cells</source>
        <year>2022</year>
        <volume>11</volume>
        <elocation-id>1443</elocation-id>
        <pub-id pub-id-type="doi">10.3390/cells11091443</pub-id>
        <?supplied-pmid 35563749?>
        <pub-id pub-id-type="pmid">35563749</pub-id>
      </element-citation>
    </ref>
    <ref id="B108-ijms-24-01891">
      <label>108.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Vassilev</surname>
            <given-names>L.T.</given-names>
          </name>
          <name>
            <surname>Vu</surname>
            <given-names>B.T.</given-names>
          </name>
          <name>
            <surname>Graves</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Carvajal</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Podlaski</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Filipovic</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Kong</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Kammlott</surname>
            <given-names>U.</given-names>
          </name>
          <name>
            <surname>Lukacs</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Klein</surname>
            <given-names>C.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>In Vivo Activation of the P53 Pathway by Small-Molecule Antagonists of MDM2</article-title>
        <source>Science</source>
        <year>2004</year>
        <volume>303</volume>
        <fpage>844</fpage>
        <lpage>848</lpage>
        <pub-id pub-id-type="doi">10.1126/science.1092472</pub-id>
        <?supplied-pmid 14704432?>
        <pub-id pub-id-type="pmid">14704432</pub-id>
      </element-citation>
    </ref>
    <ref id="B109-ijms-24-01891">
      <label>109.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lievens</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Gerlo</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Lemmens</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>De Clercq</surname>
            <given-names>D.J.H.</given-names>
          </name>
          <name>
            <surname>Risseeuw</surname>
            <given-names>M.D.P.</given-names>
          </name>
          <name>
            <surname>Vanderroost</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>De Smet</surname>
            <given-names>A.-S.</given-names>
          </name>
          <name>
            <surname>Ruyssinck</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Chevet</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Van Calenbergh</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Kinase Substrate Sensor (KISS), a Mammalian In Situ Protein Interaction Sensor</article-title>
        <source>Mol. Cell. Proteom.</source>
        <year>2014</year>
        <volume>13</volume>
        <fpage>3332</fpage>
        <lpage>3342</lpage>
        <pub-id pub-id-type="doi">10.1074/mcp.M114.041087</pub-id>
        <?supplied-pmid 25154561?>
        <pub-id pub-id-type="pmid">25154561</pub-id>
      </element-citation>
    </ref>
    <ref id="B110-ijms-24-01891">
      <label>110.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Oliner</surname>
            <given-names>J.D.</given-names>
          </name>
          <name>
            <surname>Kinzler</surname>
            <given-names>K.W.</given-names>
          </name>
          <name>
            <surname>Meltzer</surname>
            <given-names>P.S.</given-names>
          </name>
          <name>
            <surname>George</surname>
            <given-names>D.L.</given-names>
          </name>
          <name>
            <surname>Vogelstein</surname>
            <given-names>B.</given-names>
          </name>
        </person-group>
        <article-title>Amplification of a Gene Encoding a P53-Associated Protein in Human Sarcomas</article-title>
        <source>Nature</source>
        <year>1992</year>
        <volume>358</volume>
        <fpage>80</fpage>
        <lpage>83</lpage>
        <pub-id pub-id-type="doi">10.1038/358080a0</pub-id>
        <?supplied-pmid 1614537?>
        <pub-id pub-id-type="pmid">1614537</pub-id>
      </element-citation>
    </ref>
    <ref id="B111-ijms-24-01891">
      <label>111.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Bayle</surname>
            <given-names>J.H.</given-names>
          </name>
          <name>
            <surname>Olson</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Levine</surname>
            <given-names>A.J.</given-names>
          </name>
        </person-group>
        <article-title>The P53-Mdm-2 Autoregulatory Feedback Loop</article-title>
        <source>Genes Dev.</source>
        <year>1993</year>
        <volume>7</volume>
        <fpage>1126</fpage>
        <lpage>1132</lpage>
        <pub-id pub-id-type="doi">10.1101/gad.7.7a.1126</pub-id>
        <pub-id pub-id-type="pmid">8319905</pub-id>
      </element-citation>
    </ref>
    <ref id="B112-ijms-24-01891">
      <label>112.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ashcroft</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Taya</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Vousden</surname>
            <given-names>K.H.</given-names>
          </name>
        </person-group>
        <article-title>Stress Signals Utilize Multiple Pathways To Stabilize P53</article-title>
        <source>Mol. Cell. Biol.</source>
        <year>2000</year>
        <volume>20</volume>
        <fpage>3224</fpage>
        <lpage>3233</lpage>
        <pub-id pub-id-type="doi">10.1128/MCB.20.9.3224-3233.2000</pub-id>
        <pub-id pub-id-type="pmid">10757806</pub-id>
      </element-citation>
    </ref>
    <ref id="B113-ijms-24-01891">
      <label>113.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Michael</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Oren</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>The P53-Mdm2 Module and the Ubiquitin System</article-title>
        <source>Semin. Cancer Biol.</source>
        <year>2003</year>
        <volume>13</volume>
        <fpage>49</fpage>
        <lpage>58</lpage>
        <pub-id pub-id-type="doi">10.1016/S1044-579X(02)00099-8</pub-id>
        <?supplied-pmid 12507556?>
        <pub-id pub-id-type="pmid">12507556</pub-id>
      </element-citation>
    </ref>
    <ref id="B114-ijms-24-01891">
      <label>114.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sun</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Tang</surname>
            <given-names>L.</given-names>
          </name>
        </person-group>
        <article-title>MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of P53</article-title>
        <source>Curr. Med. Chem.</source>
        <year>2016</year>
        <volume>23</volume>
        <fpage>4529</fpage>
        <lpage>4539</lpage>
        <pub-id pub-id-type="doi">10.2174/0929867323666160926150820</pub-id>
        <pub-id pub-id-type="pmid">27686656</pub-id>
      </element-citation>
    </ref>
    <ref id="B115-ijms-24-01891">
      <label>115.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Qu</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>X.-Z.</given-names>
          </name>
          <name>
            <surname>Ji</surname>
            <given-names>Y.-X.</given-names>
          </name>
          <name>
            <surname>Yuan</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>S.-P.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Q.-G.</given-names>
          </name>
        </person-group>
        <article-title>Pimozide Inhibits the Growth of Breast Cancer Cells by Alleviating the Warburg Effect through the P53 Signaling Pathway</article-title>
        <source>Biomed Pharm.</source>
        <year>2022</year>
        <volume>150</volume>
        <fpage>113063</fpage>
        <pub-id pub-id-type="doi">10.1016/j.biopha.2022.113063</pub-id>
      </element-citation>
    </ref>
    <ref id="B116-ijms-24-01891">
      <label>116.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>R.W.</given-names>
          </name>
          <name>
            <surname>Chuang</surname>
            <given-names>D.M.</given-names>
          </name>
        </person-group>
        <article-title>Long Term Lithium Treatment Suppresses P53 and Bax Expression but Increases Bcl-2 Expression. A Prominent Role in Neuroprotection against Excitotoxicity</article-title>
        <source>J. Biol. Chem.</source>
        <year>1999</year>
        <volume>274</volume>
        <fpage>6039</fpage>
        <lpage>6042</lpage>
        <pub-id pub-id-type="doi">10.1074/jbc.274.10.6039</pub-id>
        <pub-id pub-id-type="pmid">10037682</pub-id>
      </element-citation>
    </ref>
    <ref id="B117-ijms-24-01891">
      <label>117.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Cao</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Ye</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Tian</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>X.</given-names>
          </name>
        </person-group>
        <article-title>The Dual Roles of MAGE-C2 in P53 Ubiquitination and Cell Proliferation through E3 Ligases MDM2 and TRIM28</article-title>
        <source>Front. Cell Dev. Biol.</source>
        <year>2022</year>
        <volume>10</volume>
        <fpage>922675</fpage>
        <pub-id pub-id-type="doi">10.3389/fcell.2022.922675</pub-id>
        <pub-id pub-id-type="pmid">35927984</pub-id>
      </element-citation>
    </ref>
    <ref id="B118-ijms-24-01891">
      <label>118.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jin</surname>
            <given-names>J.-O.</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>G.D.</given-names>
          </name>
          <name>
            <surname>Nam</surname>
            <given-names>S.H.</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>T.H.</given-names>
          </name>
          <name>
            <surname>Kang</surname>
            <given-names>D.H.</given-names>
          </name>
          <name>
            <surname>Yun</surname>
            <given-names>J.K.</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>P.C.-W.</given-names>
          </name>
        </person-group>
        <article-title>Sequential Ubiquitination of P53 by TRIM28, RLIM, and MDM2 in Lung Tumorigenesis</article-title>
        <source>Cell Death Differ.</source>
        <year>2021</year>
        <volume>28</volume>
        <fpage>1790</fpage>
        <lpage>1803</lpage>
        <pub-id pub-id-type="doi">10.1038/s41418-020-00701-y</pub-id>
        <pub-id pub-id-type="pmid">33328571</pub-id>
      </element-citation>
    </ref>
    <ref id="B119-ijms-24-01891">
      <label>119.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Luo</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Nikolaev</surname>
            <given-names>A.Y.</given-names>
          </name>
          <name>
            <surname>Imai</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Su</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Shiloh</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Guarente</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Gu</surname>
            <given-names>W.</given-names>
          </name>
        </person-group>
        <article-title>Negative Control of P53 by Sir2α Promotes Cell Survival under Stress</article-title>
        <source>Cell</source>
        <year>2001</year>
        <volume>107</volume>
        <fpage>137</fpage>
        <lpage>148</lpage>
        <pub-id pub-id-type="doi">10.1016/S0092-8674(01)00524-4</pub-id>
        <?supplied-pmid 11672522?>
        <pub-id pub-id-type="pmid">11672522</pub-id>
      </element-citation>
    </ref>
    <ref id="B120-ijms-24-01891">
      <label>120.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sakaguchi</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Herrera</surname>
            <given-names>J.E.</given-names>
          </name>
          <name>
            <surname>Saito</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Miki</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Bustin</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Vassilev</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Anderson</surname>
            <given-names>C.W.</given-names>
          </name>
          <name>
            <surname>Appella</surname>
            <given-names>E.</given-names>
          </name>
        </person-group>
        <article-title>DNA Damage Activates P53 through a Phosphorylation-Acetylation Cascade</article-title>
        <source>Genes Dev.</source>
        <year>1998</year>
        <volume>12</volume>
        <fpage>2831</fpage>
        <lpage>2841</lpage>
        <pub-id pub-id-type="doi">10.1101/gad.12.18.2831</pub-id>
        <pub-id pub-id-type="pmid">9744860</pub-id>
      </element-citation>
    </ref>
    <ref id="B121-ijms-24-01891">
      <label>121.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Brooks</surname>
            <given-names>C.L.</given-names>
          </name>
          <name>
            <surname>Gu</surname>
            <given-names>W.</given-names>
          </name>
        </person-group>
        <article-title>Ubiquitination, Phosphorylation and Acetylation: The Molecular Basis for P53 Regulation</article-title>
        <source>Curr. Opin. Cell Biol.</source>
        <year>2003</year>
        <volume>15</volume>
        <fpage>164</fpage>
        <lpage>171</lpage>
        <pub-id pub-id-type="doi">10.1016/S0955-0674(03)00003-6</pub-id>
        <pub-id pub-id-type="pmid">12648672</pub-id>
      </element-citation>
    </ref>
    <ref id="B122-ijms-24-01891">
      <label>122.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Francis</surname>
            <given-names>V.A.</given-names>
          </name>
          <name>
            <surname>Zorzano</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Teleman</surname>
            <given-names>A.A.</given-names>
          </name>
        </person-group>
        <article-title>DDOR Is an EcR Coactivator That Forms a Feed-Forward Loop Connecting Insulin and Ecdysone Signaling</article-title>
        <source>Curr. Biol.</source>
        <year>2010</year>
        <volume>20</volume>
        <fpage>1799</fpage>
        <lpage>1808</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cub.2010.08.055</pub-id>
        <?supplied-pmid 20888228?>
        <pub-id pub-id-type="pmid">20888228</pub-id>
      </element-citation>
    </ref>
    <ref id="B123-ijms-24-01891">
      <label>123.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Luck</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>D.-K.</given-names>
          </name>
          <name>
            <surname>Lambourne</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Spirohn</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Begg</surname>
            <given-names>B.E.</given-names>
          </name>
          <name>
            <surname>Bian</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Brignall</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Cafarelli</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Campos-Laborie</surname>
            <given-names>F.J.</given-names>
          </name>
          <name>
            <surname>Charloteaux</surname>
            <given-names>B.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A Reference Map of the Human Binary Protein Interactome</article-title>
        <source>Nature</source>
        <year>2020</year>
        <volume>580</volume>
        <fpage>402</fpage>
        <lpage>408</lpage>
        <pub-id pub-id-type="doi">10.1038/s41586-020-2188-x</pub-id>
        <?supplied-pmid 32296183?>
        <pub-id pub-id-type="pmid">32296183</pub-id>
      </element-citation>
    </ref>
    <ref id="B124-ijms-24-01891">
      <label>124.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Seillier</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Peuget</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Gayet</surname>
            <given-names>O.</given-names>
          </name>
          <name>
            <surname>Gauthier</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>N’Guessan</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Monte</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Carrier</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Iovanna</surname>
            <given-names>J.L.</given-names>
          </name>
          <name>
            <surname>Dusetti</surname>
            <given-names>N.J.</given-names>
          </name>
        </person-group>
        <article-title>TP53INP1, a Tumor Suppressor, Interacts with LC3 and ATG8-Family Proteins through the LC3-Interacting Region (LIR) and Promotes Autophagy-Dependent Cell Death</article-title>
        <source>Cell Death Differ.</source>
        <year>2012</year>
        <volume>19</volume>
        <fpage>1525</fpage>
        <lpage>1535</lpage>
        <pub-id pub-id-type="doi">10.1038/cdd.2012.30</pub-id>
        <pub-id pub-id-type="pmid">22421968</pub-id>
      </element-citation>
    </ref>
    <ref id="B125-ijms-24-01891">
      <label>125.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kittler</surname>
            <given-names>J.T.</given-names>
          </name>
          <name>
            <surname>Moss</surname>
            <given-names>S.J.</given-names>
          </name>
        </person-group>
        <article-title>Modulation of GABAA Receptor Activity by Phosphorylation and Receptor Trafficking: Implications for the Efficacy of Synaptic Inhibition</article-title>
        <source>Curr. Opin. Neurobiol.</source>
        <year>2003</year>
        <volume>13</volume>
        <fpage>341</fpage>
        <lpage>347</lpage>
        <pub-id pub-id-type="doi">10.1016/S0959-4388(03)00064-3</pub-id>
        <pub-id pub-id-type="pmid">12850219</pub-id>
      </element-citation>
    </ref>
    <ref id="B126-ijms-24-01891">
      <label>126.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ye</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Zou</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Kong</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Miao</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Xiong</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>C.</given-names>
          </name>
        </person-group>
        <article-title>Structural Basis of GABARAP-Mediated GABAA Receptor Trafficking and Functions on GABAergic Synaptic Transmission</article-title>
        <source>Nat. Commun.</source>
        <year>2021</year>
        <volume>12</volume>
        <fpage>297</fpage>
        <pub-id pub-id-type="doi">10.1038/s41467-020-20624-z</pub-id>
        <pub-id pub-id-type="pmid">33436612</pub-id>
      </element-citation>
    </ref>
    <ref id="B127-ijms-24-01891">
      <label>127.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Marques</surname>
            <given-names>T.R.</given-names>
          </name>
          <name>
            <surname>Ashok</surname>
            <given-names>A.H.</given-names>
          </name>
          <name>
            <surname>Angelescu</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Borgan</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Myers</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Lingford-Hughes</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Nutt</surname>
            <given-names>D.J.</given-names>
          </name>
          <name>
            <surname>Veronese</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Turkheimer</surname>
            <given-names>F.E.</given-names>
          </name>
          <name>
            <surname>Howes</surname>
            <given-names>O.D.</given-names>
          </name>
        </person-group>
        <article-title>GABA-A Receptor Differences in Schizophrenia: A Positron Emission Tomography Study Using [11C]Ro154513</article-title>
        <source>Mol. Psychiatr.</source>
        <year>2021</year>
        <volume>26</volume>
        <fpage>2616</fpage>
        <lpage>2625</lpage>
        <pub-id pub-id-type="doi">10.1038/s41380-020-0711-y</pub-id>
      </element-citation>
    </ref>
    <ref id="B128-ijms-24-01891">
      <label>128.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ueno</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Nakajima</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Iwata</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Honda</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Torres-Carmona</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Mar</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Tsugawa</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Truong</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Plitman</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Noda</surname>
            <given-names>Y.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gamma-Aminobutyric Acid (GABA) Levels in the Midcingulate Cortex and Clozapine Response in Patients with Treatment-Resistant Schizophrenia: A Proton Magnetic Resonance Spectroscopy (1H-MRS) Study</article-title>
        <source>Psychiatr. Clin. Neurosci.</source>
        <year>2022</year>
        <volume>76</volume>
        <fpage>587</fpage>
        <lpage>594</lpage>
        <pub-id pub-id-type="doi">10.1111/pcn.13463</pub-id>
        <?supplied-pmid 36111425?>
        <pub-id pub-id-type="pmid">36111425</pub-id>
      </element-citation>
    </ref>
    <ref id="B129-ijms-24-01891">
      <label>129.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Park</surname>
            <given-names>J.K.</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>H.J.</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>J.W.</given-names>
          </name>
          <name>
            <surname>Park</surname>
            <given-names>Y.H.</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>S.S.</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>H.I.</given-names>
          </name>
          <name>
            <surname>Song</surname>
            <given-names>J.Y.</given-names>
          </name>
          <name>
            <surname>Yoon</surname>
            <given-names>D.J.</given-names>
          </name>
          <name>
            <surname>Bahn</surname>
            <given-names>G.H.</given-names>
          </name>
          <name>
            <surname>Shin</surname>
            <given-names>Y.H.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Differences in P53 Gene Polymorphisms between Korean Schizophrenia and Lung Cancer Patients</article-title>
        <source>Schizophr. Res.</source>
        <year>2004</year>
        <volume>67</volume>
        <fpage>71</fpage>
        <lpage>74</lpage>
        <pub-id pub-id-type="doi">10.1016/S0920-9964(03)00155-5</pub-id>
        <?supplied-pmid 14741326?>
        <pub-id pub-id-type="pmid">14741326</pub-id>
      </element-citation>
    </ref>
    <ref id="B130-ijms-24-01891">
      <label>130.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Catts</surname>
            <given-names>V.S.</given-names>
          </name>
          <name>
            <surname>Catts</surname>
            <given-names>S.V.</given-names>
          </name>
        </person-group>
        <article-title>Apoptosis and Schizophrenia: Is the Tumour Suppressor Gene, P53, a Candidate Susceptibility Gene?</article-title>
        <source>Schizophr. Res.</source>
        <year>2000</year>
        <volume>41</volume>
        <fpage>405</fpage>
        <lpage>415</lpage>
        <pub-id pub-id-type="doi">10.1016/S0920-9964(99)00077-8</pub-id>
        <?supplied-pmid 10728718?>
        <pub-id pub-id-type="pmid">10728718</pub-id>
      </element-citation>
    </ref>
    <ref id="B131-ijms-24-01891">
      <label>131.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Xiao</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Sang</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Guan</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Peng</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Gu</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Qian</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>G.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Tumor Suppressor Gene TP53 Is Genetically Associated with Schizophrenia in the Chinese Population</article-title>
        <source>Neurosci. Lett.</source>
        <year>2004</year>
        <volume>369</volume>
        <fpage>126</fpage>
        <lpage>131</lpage>
        <pub-id pub-id-type="doi">10.1016/j.neulet.2004.07.068</pub-id>
        <pub-id pub-id-type="pmid">15450681</pub-id>
      </element-citation>
    </ref>
    <ref id="B132-ijms-24-01891">
      <label>132.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Molina</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Papiol</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Sanz</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Rosa</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Arias</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Fatjó-Vilas</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Calama</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Hernández</surname>
            <given-names>A.I.</given-names>
          </name>
          <name>
            <surname>Bécker</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Fañanás</surname>
            <given-names>L.</given-names>
          </name>
        </person-group>
        <article-title>Convergent Evidence of the Contribution of TP53 Genetic Variation (Pro72Arg) to Metabolic Activity and White Matter Volume in the Frontal Lobe in Schizophrenia Patients</article-title>
        <source>NeuroImage</source>
        <year>2011</year>
        <volume>56</volume>
        <fpage>45</fpage>
        <lpage>51</lpage>
        <pub-id pub-id-type="doi">10.1016/j.neuroimage.2011.01.076</pub-id>
        <pub-id pub-id-type="pmid">21296169</pub-id>
      </element-citation>
    </ref>
    <ref id="B133-ijms-24-01891">
      <label>133.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fang</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Ren</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>C.</given-names>
          </name>
        </person-group>
        <article-title>Depressive Symptoms in Schizophrenia Patients: A Possible Relationship between SIRT1 and BDNF</article-title>
        <source>Prog. Neuro-Psychopharmacol. Biol. Psychiatr.</source>
        <year>2019</year>
        <volume>95</volume>
        <fpage>109673</fpage>
        <pub-id pub-id-type="doi">10.1016/j.pnpbp.2019.109673</pub-id>
      </element-citation>
    </ref>
    <ref id="B134-ijms-24-01891">
      <label>134.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Tang</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Fan</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>C.</given-names>
          </name>
        </person-group>
        <article-title>A Comprehensive Analysis of the Effect of SIRT1 Variation on the Risk of Schizophrenia and Depressive Symptoms</article-title>
        <source>Front. Genet.</source>
        <year>2020</year>
        <volume>11</volume>
        <fpage>832</fpage>
        <pub-id pub-id-type="doi">10.3389/fgene.2020.00832</pub-id>
        <pub-id pub-id-type="pmid">32849821</pub-id>
      </element-citation>
    </ref>
    <ref id="B135-ijms-24-01891">
      <label>135.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Niu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Cao</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Ji</surname>
            <given-names>Y.</given-names>
          </name>
        </person-group>
        <article-title>Resveratrol, a SIRT1 Activator, Ameliorates MK-801-Induced Cognitive and Motor Impairments in a Neonatal Rat Model of Schizophrenia</article-title>
        <source>Front. Psychiatr.</source>
        <year>2020</year>
        <volume>11</volume>
        <fpage>716</fpage>
        <pub-id pub-id-type="doi">10.3389/fpsyt.2020.00716</pub-id>
      </element-citation>
    </ref>
    <ref id="B136-ijms-24-01891">
      <label>136.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dong</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Agis-Balboa</surname>
            <given-names>R.C.</given-names>
          </name>
          <name>
            <surname>Simonini</surname>
            <given-names>M.V.</given-names>
          </name>
          <name>
            <surname>Grayson</surname>
            <given-names>D.R.</given-names>
          </name>
          <name>
            <surname>Costa</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Guidotti</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>Reelin and Glutamic Acid Decarboxylase <sub>67</sub> Promoter Remodeling in an Epigenetic Methionine-Induced Mouse Model of Schizophrenia</article-title>
        <source>Proc. Natl. Acad. Sci. USA</source>
        <year>2005</year>
        <volume>102</volume>
        <fpage>12578</fpage>
        <lpage>12583</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.0505394102</pub-id>
        <pub-id pub-id-type="pmid">16113080</pub-id>
      </element-citation>
    </ref>
    <ref id="B137-ijms-24-01891">
      <label>137.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Saxena</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Choudhury</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Maroju</surname>
            <given-names>P.A.</given-names>
          </name>
          <name>
            <surname>Anne</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Kumar</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Mohan</surname>
            <given-names>K.N.</given-names>
          </name>
        </person-group>
        <article-title>Dysregulation of Schizophrenia-Associated Genes and Genome-Wide Hypomethylation in Neurons Overexpressing DNMT1</article-title>
        <source>Epigenomics</source>
        <year>2021</year>
        <volume>13</volume>
        <fpage>1539</fpage>
        <lpage>1555</lpage>
        <pub-id pub-id-type="doi">10.2217/epi-2021-0133</pub-id>
        <?supplied-pmid 34647491?>
        <pub-id pub-id-type="pmid">34647491</pub-id>
      </element-citation>
    </ref>
    <ref id="B138-ijms-24-01891">
      <label>138.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dong</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Ruzicka</surname>
            <given-names>W.B.</given-names>
          </name>
          <name>
            <surname>Grayson</surname>
            <given-names>D.R.</given-names>
          </name>
          <name>
            <surname>Guidotti</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>DNA-Methyltransferase1 (DNMT1) Binding to CpG Rich GABAergic and BDNF Promoters Is Increased in the Brain of Schizophrenia and Bipolar Disorder Patients</article-title>
        <source>Schizophr. Res.</source>
        <year>2015</year>
        <volume>167</volume>
        <fpage>35</fpage>
        <lpage>41</lpage>
        <pub-id pub-id-type="doi">10.1016/j.schres.2014.10.030</pub-id>
        <?supplied-pmid 25476119?>
        <pub-id pub-id-type="pmid">25476119</pub-id>
      </element-citation>
    </ref>
    <ref id="B139-ijms-24-01891">
      <label>139.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Veldic</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Kadriu</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Maloku</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Agis-Balboa</surname>
            <given-names>R.C.</given-names>
          </name>
          <name>
            <surname>Guidotti</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Davis</surname>
            <given-names>J.M.</given-names>
          </name>
          <name>
            <surname>Costa</surname>
            <given-names>E.</given-names>
          </name>
        </person-group>
        <article-title>Epigenetic Mechanisms Expressed in Basal Ganglia GABAergic Neurons Differentiate Schizophrenia from Bipolar Disorder</article-title>
        <source>Schizophr. Res.</source>
        <year>2007</year>
        <volume>91</volume>
        <fpage>51</fpage>
        <lpage>61</lpage>
        <pub-id pub-id-type="doi">10.1016/j.schres.2006.11.029</pub-id>
        <pub-id pub-id-type="pmid">17270400</pub-id>
      </element-citation>
    </ref>
    <ref id="B140-ijms-24-01891">
      <label>140.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kay</surname>
            <given-names>S.R.</given-names>
          </name>
          <name>
            <surname>Fiszbein</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Opler</surname>
            <given-names>L.A.</given-names>
          </name>
        </person-group>
        <article-title>The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia</article-title>
        <source>Schizophr. Bull.</source>
        <year>1987</year>
        <volume>13</volume>
        <fpage>261</fpage>
        <lpage>276</lpage>
        <pub-id pub-id-type="doi">10.1093/schbul/13.2.261</pub-id>
        <pub-id pub-id-type="pmid">3616518</pub-id>
      </element-citation>
    </ref>
    <ref id="B141-ijms-24-01891">
      <label>141.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Olivares</surname>
            <given-names>J.M.</given-names>
          </name>
          <name>
            <surname>Berrios</surname>
            <given-names>G.E.</given-names>
          </name>
          <name>
            <surname>Bousoño</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>The Self-Assessment Anhedonia Scale (SAAS)</article-title>
        <source>Neurol. Psychiatr. Brain Res.</source>
        <year>2005</year>
        <volume>12</volume>
        <fpage>121</fpage>
        <lpage>134</lpage>
      </element-citation>
    </ref>
    <ref id="B142-ijms-24-01891">
      <label>142.</label>
      <element-citation publication-type="gov">
        <article-title>GRCh38—Hg38—Genome—Assembly—NCBI</article-title>
        <comment>Available online: <ext-link xlink:href="https://www.ncbi.nlm.nih.gov/assembly/GCF_000001405.26/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/assembly/GCF_000001405.26/</ext-link></comment>
        <date-in-citation content-type="access-date" iso-8601-date="2022-11-14">(accessed on 14 November 2022)</date-in-citation>
      </element-citation>
    </ref>
    <ref id="B143-ijms-24-01891">
      <label>143.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kozomara</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Birgaoanu</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Griffiths-Jones</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>MiRBase: From MicroRNA Sequences to Function</article-title>
        <source>Nucl. Acids Res.</source>
        <year>2019</year>
        <volume>47</volume>
        <fpage>D155</fpage>
        <lpage>D162</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gky1141</pub-id>
        <?supplied-pmid 30423142?>
        <pub-id pub-id-type="pmid">30423142</pub-id>
      </element-citation>
    </ref>
    <ref id="B144-ijms-24-01891">
      <label>144.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Love</surname>
            <given-names>M.I.</given-names>
          </name>
          <name>
            <surname>Huber</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Anders</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>Moderated Estimation of Fold Change and Dispersion for RNA-Seq Data with DESeq2</article-title>
        <source>Genome Biol.</source>
        <year>2014</year>
        <volume>15</volume>
        <fpage>550</fpage>
        <pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id>
        <?supplied-pmid 25516281?>
        <pub-id pub-id-type="pmid">25516281</pub-id>
      </element-citation>
    </ref>
    <ref id="B145-ijms-24-01891">
      <label>145.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Carlin</surname>
            <given-names>D.E.</given-names>
          </name>
          <name>
            <surname>Demchak</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Pratt</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Sage</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Ideker</surname>
            <given-names>T.</given-names>
          </name>
        </person-group>
        <article-title>Network Propagation in the Cytoscape Cyberinfrastructure</article-title>
        <source>PLoS Comput. Biol.</source>
        <year>2017</year>
        <volume>13</volume>
        <elocation-id>e1005598</elocation-id>
        <pub-id pub-id-type="doi">10.1371/journal.pcbi.1005598</pub-id>
        <pub-id pub-id-type="pmid">29023449</pub-id>
      </element-citation>
    </ref>
    <ref id="B146-ijms-24-01891">
      <label>146.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <collab>The UniProt Consortium</collab>
        </person-group>
        <article-title>UniProt: The Universal Protein Knowledgebase in 2021</article-title>
        <source>Nucl. Acids Res.</source>
        <year>2021</year>
        <volume>49</volume>
        <fpage>D480</fpage>
        <lpage>D489</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkaa1100</pub-id>
        <pub-id pub-id-type="pmid">33237286</pub-id>
      </element-citation>
    </ref>
    <ref id="B147-ijms-24-01891">
      <label>147.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gillespie</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Jassal</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Stephan</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Milacic</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Rothfels</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Senff-Ribeiro</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Griss</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Sevilla</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Matthews</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Gong</surname>
            <given-names>C.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The Reactome Pathway Knowledgebase 2022</article-title>
        <source>Nucl. Acids Res.</source>
        <year>2022</year>
        <volume>50</volume>
        <fpage>D687</fpage>
        <lpage>D692</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkab1028</pub-id>
        <pub-id pub-id-type="pmid">34788843</pub-id>
      </element-citation>
    </ref>
    <ref id="B148-ijms-24-01891">
      <label>148.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Martens</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Ammar</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Riutta</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Waagmeester</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Slenter</surname>
            <given-names>D.N.</given-names>
          </name>
          <name>
            <surname>Hanspers</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Miller</surname>
            <given-names>R.A.</given-names>
          </name>
          <name>
            <surname>Digles</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Lopes</surname>
            <given-names>E.N.</given-names>
          </name>
          <name>
            <surname>Ehrhart</surname>
            <given-names>F.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>WikiPathways: Connecting Communities</article-title>
        <source>Nucl. Acids Res.</source>
        <year>2021</year>
        <volume>49</volume>
        <fpage>D613</fpage>
        <lpage>D621</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkaa1024</pub-id>
        <?supplied-pmid 33211851?>
        <pub-id pub-id-type="pmid">33211851</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
<floats-group>
  <fig position="float" id="ijms-24-01891-f001">
    <label>Figure 1</label>
    <caption>
      <p>(<bold>A</bold>) Heatmap with the results of the hierarchical clustering of MR and MNR samples. (<bold>B</bold>) Box-plots with the MR and MNR punctuations on the PANSS general, positive, negative, and SAAS scales. The overlap between both groups can be seen. (<bold>C</bold>) Hierarchical clustering with MR samples (blue) and MNR samples (red); more than 70% of samples of both conditions were clustered homogeneously. (<bold>D</bold>) Hierarchical clustering with samples in MR, MNR, and PA groups. MR samples are colored in blue, MNR samples in red and PA samples were marked with a dot and colored in blue or red depending on the evolution of their psychotic episode.</p>
    </caption>
    <graphic xlink:href="ijms-24-01891-g001" position="float"/>
  </fig>
  <fig position="float" id="ijms-24-01891-f002">
    <label>Figure 2</label>
    <caption>
      <p>Molecular interactions deduced from the most connected nodes of the network.</p>
    </caption>
    <graphic xlink:href="ijms-24-01891-g002" position="float"/>
  </fig>
  <fig position="float" id="ijms-24-01891-f003">
    <label>Figure 3</label>
    <caption>
      <p>Pathway in which differentially expressed miRNAs could be involved, potentially related to the antipsychotic resistance in schizophrenia. MiRNAs are colored according to their expression in the MNR group when compared to the MR group; red indicates overexpression and blue underexpression. Sirtuin 1 (SIRT1) interacts with the DNA Methyltransferase 1 (DNMT1) and the Tumor Protein P53 (p53) regulating its expression. Proteins MDM2 Proto-Oncogene (MDM2), MAGE Family Member C2 (MAGEC2), and RING Finger Protein 96 (TRIM28) are closely linked with p53 inactivation and heavily targeted by the miRNAs of our TRS profile. This inactivation of p53 is through ubiquitination (p53<sup>Ub</sup>), which leads to its degradation. Acetylated p53 (p53<sup>Ac</sup>) acts as a transcriptional factor of several genes, from which Tumor Protein P53 Inducible Nuclear Protein 1 (TP53INP1) is the one most targeted by the TRS profile. This protein is a positive regulator of the autophagy and also acts as a transcription regulator in response to cellular stress. This regulation is made through its interaction with GABA Type A Receptor-Associated Protein (GABARAP), with GABA Type A Receptor Associated Protein Like 1/2 (GABARAPL1, GABARAPL2) and with Microtubule Associated Protein 1 Light Chain 3 Alpha/Beta/Gamma (MAP1LC3A, MAP1LC3B, MAP1LC3B).</p>
    </caption>
    <graphic xlink:href="ijms-24-01891-g003" position="float"/>
  </fig>
  <table-wrap position="float" id="ijms-24-01891-t001">
    <object-id pub-id-type="pii">ijms-24-01891-t001_Table 1</object-id>
    <label>Table 1</label>
    <caption>
      <p>Number of targets per miRNA of the TRS profile returned by TarBase v.8 (Targets in TarBase) and found in the literature (Literature targets).</p>
    </caption>
    <table frame="hsides" rules="groups">
      <thead>
        <tr>
          <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name</th>
          <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Targets in TarBase</th>
          <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Literature Targets</th>
          <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Literature Reference</th>
        </tr>
      </thead>
      <tbody>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-210-3p</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">4075</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">ABCC1</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B28-ijms-24-01891" ref-type="bibr">28</xref>]</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-1343-3p</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">3148</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">CYP2C19</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B29-ijms-24-01891" ref-type="bibr">29</xref>]</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-30b-5p</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">2688</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">SOCS1, SOCS3</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B30-ijms-24-01891" ref-type="bibr">30</xref>]</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-145-5p</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">940</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-296-5p</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">547</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-199a-5p</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">396</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">STAT3</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B31-ijms-24-01891" ref-type="bibr">31</xref>]</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-500a-3p</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">371</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">SOCS2, SOCS4, PTPN11</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B32-ijms-24-01891" ref-type="bibr">32</xref>]</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-3127-3p</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">354</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">RAP2A</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B33-ijms-24-01891" ref-type="bibr">33</xref>]</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-3615</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">274</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-504-5p</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">263</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-223-3p</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">114</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">ABCB1</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B34-ijms-24-01891" ref-type="bibr">34</xref>]</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-3605-3p</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">97</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-548ac</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-548ay-3p</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">hsa-miR-660-5p</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
        </tr>
        <tr>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hsa-miR-6747-3p</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
        </tr>
      </tbody>
    </table>
  </table-wrap>
  <table-wrap position="float" id="ijms-24-01891-t002">
    <object-id pub-id-type="pii">ijms-24-01891-t002_Table 2</object-id>
    <label>Table 2</label>
    <caption>
      <p>Top 5 enriched pathways per database (Reactome Pathways, WikiPathways, and KEGG Pathways). The column “Gene” is the number of genes in the network associated with each pathway term. The column “Proportion” is the ratio between the number of genes with that term divided by the total number of genes in the network (<italic toggle="yes">n =</italic> 3718).</p>
    </caption>
    <table frame="hsides" rules="groups">
      <thead>
        <tr>
          <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Database</th>
          <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pathway</th>
          <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Genes</th>
          <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">FDR Value</th>
          <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Proportion</th>
        </tr>
      </thead>
      <tbody>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">Reactome Pathways</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">Metabolism of proteins</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">660</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">5.03 × 10<sup>−52</sup></td>
          <td align="center" valign="middle" rowspan="1" colspan="1">17.75%</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">Reactome Pathways</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">Gene expression (Transcription)</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">536</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">1.6 × 10<sup>−51</sup></td>
          <td align="center" valign="middle" rowspan="1" colspan="1">14.42%</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">Reactome Pathways</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">Cellular responses to stress</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">278</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">1.73 × 10<sup>−44</sup></td>
          <td align="center" valign="middle" rowspan="1" colspan="1">7.48%</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">Reactome Pathways</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">Disease</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">525</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">3.89 × 10<sup>−42</sup></td>
          <td align="center" valign="middle" rowspan="1" colspan="1">14.12%</td>
        </tr>
        <tr>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reactome Pathways</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metabolism of RNA</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">299</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.99 × 10<sup>−40</sup></td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.04%</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">WikiPathways</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">VEGFA-VEGFR2 signaling pathway</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">205</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">4.44 × 10<sup>−29</sup></td>
          <td align="center" valign="middle" rowspan="1" colspan="1">5.51%</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">WikiPathways</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">Alzheimer’s disease and miRNA effects</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">129</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">3.6 × 10<sup>−19</sup></td>
          <td align="center" valign="middle" rowspan="1" colspan="1">3.47%</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">WikiPathways</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">DNA IR-damage and cellular response via ATR</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">64</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">8.38 × 10<sup>−17</sup></td>
          <td align="center" valign="middle" rowspan="1" colspan="1">1.72%</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">WikiPathways</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">Integrated breast cancer pathway</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">89</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">1.39 × 10<sup>−16</sup></td>
          <td align="center" valign="middle" rowspan="1" colspan="1">2.39%</td>
        </tr>
        <tr>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WikiPathways</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Androgen receptor signaling pathway</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.94 × 10<sup>−15</sup></td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.75%</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">KEGG Pathways</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">Shigellosis</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">122</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">3.57 × 10<sup>−21</sup></td>
          <td align="center" valign="middle" rowspan="1" colspan="1">3.28%</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">KEGG Pathways</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">Amyotrophic lateral sclerosis</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">148</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">4.07 × 10<sup>−17</sup></td>
          <td align="center" valign="middle" rowspan="1" colspan="1">3.98%</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">KEGG Pathways</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">Viral carcinogenesis</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">99</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">6.45 × 10<sup>−17</sup></td>
          <td align="center" valign="middle" rowspan="1" colspan="1">2.66%</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">KEGG Pathways</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">Parkinson disease</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">110</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">9.04 × 10<sup>−15</sup></td>
          <td align="center" valign="middle" rowspan="1" colspan="1">2.96%</td>
        </tr>
        <tr>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KEGG Pathways</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Huntington disease</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">125</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.41 × 10<sup>−14</sup></td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.36%</td>
        </tr>
      </tbody>
    </table>
  </table-wrap>
  <table-wrap position="float" id="ijms-24-01891-t003">
    <object-id pub-id-type="pii">ijms-24-01891-t003_Table 3</object-id>
    <label>Table 3</label>
    <caption>
      <p>Summary of the samples included in this study.</p>
    </caption>
    <table frame="hsides" rules="groups">
      <thead>
        <tr>
          <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phenotype</th>
          <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Males</th>
          <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">n</th>
          <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><inline-formula><mml:math id="mm1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi mathvariant="normal">x</mml:mi><mml:mo>-</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:math></inline-formula> Age</th>
          <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Alcohol</th>
          <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Tobacco</th>
          <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Illegal</th>
        </tr>
      </thead>
      <tbody>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">P</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">69.23%</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">13</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">32.1</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">6</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">6</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">6</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">MR</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">73.68%</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">19</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">40.0</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">5</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">11</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">12</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">MNR</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">61.90%</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">21</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">39.7</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">7</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">12</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">7</td>
        </tr>
        <tr>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55.81%</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41.5</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td>
        </tr>
        <tr>
          <td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Total</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39.5</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td>
        </tr>
      </tbody>
    </table>
  </table-wrap>
</floats-group>
